Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Previous issues

Page Path
HOME > Articles and issues > Previous issues
11 Previous issues
Filter
Filter
Article category
Keywords
Authors
Funded articles
Volume 54(1); January 2020
Prev issue Next issue
Reviews
Standardized Pathology Report for Colorectal Cancer, 2nd Edition
Baek-hui Kim, Joon Mee Kim, Gyeong Hoon Kang, Hee Jin Chang, Dong Wook Kang, Jung Ho Kim, Jeong Mo Bae, An Na Seo, Ho Sung Park, Yun Kyung Kang, Kyung-Hwa Lee, Mee Yon Cho, In-Gu Do, Hye Seung Lee, Hee Kyung Chang, Do Youn Park, Hyo Jeong Kang, Jin Hee Sohn, Mee Soo Chang, Eun Sun Jung, So-Young Jin, Eunsil Yu, Hye Seung Han, Youn Wha Kim
J Pathol Transl Med. 2020;54(1):1-19.   Published online November 13, 2019
DOI: https://doi.org/10.4132/jptm.2019.09.28
  • 17,763 View
  • 1,107 Download
  • 37 Web of Science
  • 33 Crossref
AbstractAbstract PDFSupplementary Material
The first edition of the ‘Standardized Pathology Report for Colorectal Cancer,’ which was developed by the Gastrointestinal Pathology Study Group (GIP) of the Korean Society of Pathologists, was published 13 years ago. Meanwhile, there have been many changes in the pathologic diagnosis of colorectal cancer (CRC), pathologic findings included in the pathology report, and immunohistochemical and molecular pathology required for the diagnosis and treatment of colorectal cancer. In order to reflect these changes, we (GIP) decided to make the second edition of the report. The purpose of this standardized pathology report is to provide a practical protocol for Korean pathologists, which could help diagnose and treat CRC patients. This report consists of “standard data elements” and “conditional data elements.” Basic pathologic findings and parts necessary for prognostication of CRC patients are classified as “standard data elements,” while other prognostic factors and factors related to adjuvant therapy are classified as “conditional data elements” so that each institution could select the contents according to the characteristics of the institution. The Korean version is also provided separately so that Korean pathologists can easily understand and use this report. We hope that this report will be helpful in the daily practice of CRC diagnosis.

Citations

Citations to this article as recorded by  
  • The use of core descriptors from the ENiGMA code study in recent literature: a systematic review
    Saher‐Zahra Khan, Andrea Arline, Kate M. Williams, Matthew J. Lee, Emily Steinhagen, Sharon L. Stein
    Colorectal Disease.2024; 26(3): 428.     CrossRef
  • Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study
    Zhengyang Yang, Jiale Gao, Jianyong Zheng, Jiagang Han, Ang Li, Gang Liu, Yi Sun, Jie Zhang, Guangyong Chen, Rui Xu, Xiao Zhang, Yishan Liu, Zhigang Bai, Wei Deng, Wei He, Hongwei Yao, Zhongtao Zhang
    Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
  • Diagnostic Accuracy of Highest-Grade or Predominant Histological Differentiation of T1 Colorectal Cancer in Predicting Lymph Node Metastasis: A Systematic Review and Meta-Analysis
    Jun Watanabe, Katsuro Ichimasa, Yuki Kataoka, Shoko Miyahara, Atsushi Miki, Khay Guan Yeoh, Shigeo Kawai, Fernando Martínez de Juan, Isidro Machado, Kazuhiko Kotani, Naohiro Sata
    Clinical and Translational Gastroenterology.2024; 15(3): e00673.     CrossRef
  • Pathologic Implications of Magnetic Resonance Imaging-detected Extramural Venous Invasion of Rectal Cancer
    Hyun Gu Lee, Chan Wook Kim, Jong Keon Jang, Seong Ho Park, Young Il Kim, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Clinical Colorectal Cancer.2023; 22(1): 129.     CrossRef
  • A standardized pathology report for gastric cancer: 2nd edition
    Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
    Journal of Pathology and Translational Medicine.2023; 57(1): 1.     CrossRef
  • IGFL2-AS1, a Long Non-Coding RNA, Is Associated with Radioresistance in Colorectal Cancer
    Jeeyong Lee, Da Yeon Kim, Younjoo Kim, Ui Sup Shin, Kwang Seok Kim, Eun Ju Kim
    International Journal of Molecular Sciences.2023; 24(2): 978.     CrossRef
  • A Standardized Pathology Report for Gastric Cancer: 2nd Edition
    Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
    Journal of Gastric Cancer.2023; 23(1): 107.     CrossRef
  • Incremental Detection Rate of Dysplasia and Sessile Serrated Polyps/Adenomas Using Narrow-Band Imaging and Dye Spray Chromoendoscopy in Addition to High-Definition Endoscopy in Patients with Long-Standing Extensive Ulcerative Colitis: Segmental Tandem End
    Ji Eun Kim, Chang Wan Choi, Sung Noh Hong, Joo Hye Song, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
    Diagnostics.2023; 13(3): 516.     CrossRef
  • Prognostic Impact of Extramural Lymphatic, Vascular, and Perineural Invasion in Stage II Colon Cancer: A Comparison With Intramural Invasion
    Sang Sik Cho, Ji Won Park, Gyeong Hoon Kang, Jung Ho Kim, Jeong Mo Bae, Sae-Won Han, Tae-You Kim, Min Jung Kim, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park
    Diseases of the Colon & Rectum.2023; 66(3): 366.     CrossRef
  • Towards targeted colorectal cancer biopsy based on tissue morphology assessment by compression optical coherence elastography
    Anton A. Plekhanov, Marina A. Sirotkina, Ekaterina V. Gubarkova, Elena B. Kiseleva, Alexander A. Sovetsky, Maria M. Karabut, Vladimir E. Zagainov, Sergey S. Kuznetsov, Anna V. Maslennikova, Elena V. Zagaynova, Vladimir Y. Zaitsev, Natalia D. Gladkova
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Is High-Grade Tumor Budding an Independent Prognostic Factor in Stage II Colon Cancer?
    Jung Kyong Shin, Yoon Ah Park, Jung Wook Huh, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Seok Hyung Kim, Sang Yun Ha, Yong Beom Cho
    Diseases of the Colon & Rectum.2023; 66(8): e801.     CrossRef
  • Detection of Human cytomegalovirus UL55 Gene and IE/E Protein Expression in Colorectal Cancer Patients in Egypt
    May Raouf, Ahmed A. Sabry, Mahinour A. Ragab, Samar El Achy, Amira Amer
    BMC Cancer.2023;[Epub]     CrossRef
  • Additional staining for lymphovascular invasion is associated with increased estimation of lymph node metastasis in patients with T1 colorectal cancer: Systematic review and meta‐analysis
    Jun Watanabe, Katsuro Ichimasa, Yuki Kataoka, Atsushi Miki, Hidehiro Someko, Munenori Honda, Makiko Tahara, Takeshi Yamashina, Khay Guan Yeoh, Shigeo Kawai, Kazuhiko Kotani, Naohiro Sata
    Digestive Endoscopy.2023;[Epub]     CrossRef
  • Polo-like kinase 4 as a potential predictive biomarker of chemoradioresistance in locally advanced rectal cancer
    Hyunseung Oh, Soon Gu Kim, Sung Uk Bae, Sang Jun Byun, Shin Kim, Jae-Ho Lee, Ilseon Hwang, Sun Young Kwon, Hye Won Lee
    Journal of Pathology and Translational Medicine.2022; 56(1): 40.     CrossRef
  • A Prediction Model for Tumor Recurrence in Stage II–III Colorectal Cancer Patients: From a Machine Learning Model to Genomic Profiling
    Po-Chuan Chen, Yu-Min Yeh, Bo-Wen Lin, Ren-Hao Chan, Pei-Fang Su, Yi-Chia Liu, Chung-Ta Lee, Shang-Hung Chen, Peng-Chan Lin
    Biomedicines.2022; 10(2): 340.     CrossRef
  • Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1
    Zhengyang Yang, Xiao Zhang, Jie Zhang, Jiale Gao, Zhigang Bai, Wei Deng, Guangyong Chen, Yongbo An, Yishan Liu, Qi Wei, Jiagang Han, Ang Li, Gang Liu, Yi Sun, Dalu Kong, Hongwei Yao, Zhongtao Zhang
    BMC Cancer.2022;[Epub]     CrossRef
  • Potential of DEK proto‑oncogene as a prognostic biomarker for colorectal cancer: An evidence‑based review
    Muhammad Habiburrahman, Muhammad Wardoyo, Stefanus Sutopo, Nur Rahadiani
    Molecular and Clinical Oncology.2022;[Epub]     CrossRef
  • Reproducibility and Feasibility of Classification and National Guidelines for Histological Diagnosis of Canine Mammary Gland Tumours: A Multi-Institutional Ring Study
    Serenella Papparella, Maria Crescio, Valeria Baldassarre, Barbara Brunetti, Giovanni Burrai, Cristiano Cocumelli, Valeria Grieco, Selina Iussich, Lorella Maniscalco, Francesca Mariotti, Francesca Millanta, Orlando Paciello, Roberta Rasotto, Mariarita Roma
    Veterinary Sciences.2022; 9(7): 357.     CrossRef
  • Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer
    Jeong-ki Kim, Ye-Young Rhee, Jeong Mo Bae, Jung Ho Kim, Seong-Joon Koh, Hyun Jung Lee, Jong Pil Im, Min Jung Kim, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park, Ji Won Park, Gyeong Hoon Kang
    BMC Cancer.2022;[Epub]     CrossRef
  • Automated Hybrid Model for Detecting Perineural Invasion in the Histology of Colorectal Cancer
    Jiyoon Jung, Eunsu Kim, Hyeseong Lee, Sung Hak Lee, Sangjeong Ahn
    Applied Sciences.2022; 12(18): 9159.     CrossRef
  • Clinical Implication of Perineural and Lymphovascular Invasion in Rectal Cancer Patients Who Underwent Surgery After Preoperative Chemoradiotherapy
    Young Il Kim, Chan Wook Kim, Jong Hoon Kim, Jihun Kim, Jun-Soo Ro, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Diseases of the Colon & Rectum.2022; 65(11): 1325.     CrossRef
  • Molecular Pathology of Gastric Cancer
    Moonsik Kim, An Na Seo
    Journal of Gastric Cancer.2022; 22(4): 264.     CrossRef
  • Selective approach to arterial ligation in radical sigmoid colon cancer surgery with D3 lymph node dissection: A multicenter comparative study
    Sergey Efetov, Albina Zubayraeva, Cüneyt Kayaalp, Alisa Minenkova, Yusuf Bağ, Aftandil Alekberzade, Petr Tsarkov
    Turkish Journal of Surgery.2022; 38(4): 382.     CrossRef
  • Evaluation of lncRNA FOXD2-AS1 Expression as a Diagnostic Biomarker in Colorectal Cancer
    Hooman Shalmashi, Sahar Safaei, Dariush Shanehbandi, Milad Asadi, Soghra Bornehdeli, Abdolreza Mehdi Navaz
    Reports of Biochemistry and Molecular Biology.2022; 11(3): 471.     CrossRef
  • Improvement in the Assessment of Response to Preoperative Chemoradiotherapy for Rectal Cancer Using Magnetic Resonance Imaging and a Multigene Biomarker
    Eunhae Cho, Sung Woo Jung, In Ja Park, Jong Keon Jang, Seong Ho Park, Seung-Mo Hong, Jong Lyul Lee, Chan Wook Kim, Yong Sik Yoon, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Cancers.2021; 13(14): 3480.     CrossRef
  • Addition of V-Stage to Conventional TNM Staging to Create the TNVM Staging System for Accurate Prediction of Prognosis in Colon Cancer: A Multi-Institutional Retrospective Cohort Study
    Jung Hoon Bae, Ji Hoon Kim, Jaeim Lee, Bong-Hyeon Kye, Sang Chul Lee, In Kyu Lee, Won Kyung Kang, Hyeon-Min Cho, Yoon Suk Lee
    Biomedicines.2021; 9(8): 888.     CrossRef
  • Gene Expression Profiles Associated with Radio-Responsiveness in Locally Advanced Rectal Cancer
    Jeeyong Lee, Junhye Kwon, DaYeon Kim, Misun Park, KwangSeok Kim, InHwa Bae, Hyunkyung Kim, JoonSeog Kong, Younjoo Kim, UiSup Shin, EunJu Kim
    Biology.2021; 10(6): 500.     CrossRef
  • A Patient-Derived Organoid-Based Radiosensitivity Model for the Prediction of Radiation Responses in Patients with Rectal Cancer
    Misun Park, Junhye Kwon, Joonseog Kong, Sun Mi Moon, Sangsik Cho, Ki Young Yang, Won Il Jang, Mi Sook Kim, Younjoo Kim, Ui Sup Shin
    Cancers.2021; 13(15): 3760.     CrossRef
  • Comparison between Local Excision and Radical Resection for the Treatment of Rectal Cancer in ypT0-1 Patients: An Analysis of the Clinicopathological Factors and Survival Rates
    Soo Young Oh, In Ja Park, Young IL Kim, Jong-Lyul Lee, Chan Wook Kim, Yong Sik Yoon, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Cancers.2021; 13(19): 4823.     CrossRef
  • Comparison of Vascular Invasion With Lymph Node Metastasis as a Prognostic Factor in Stage I-III Colon Cancer: An Observational Cohort Study
    Jung Hoon Bae, Ji Hoon Kim, Bong-Hyeon Kye, Abdullah Al-Sawat, Chul Seung Lee, Seung-Rim Han, In Kyu Lee, Sung Hak Lee, Yoon Suk Lee
    Frontiers in Surgery.2021;[Epub]     CrossRef
  • Clinicopathological significance of Ki67 expression in colorectal cancer
    Jing Li, Zhi-ye Liu, Hai-bo Yu, Qing Xue, Wen-jie He, Hai-tao Yu
    Medicine.2020; 99(20): e20136.     CrossRef
  • Lateral lymph node and its association with distant recurrence in rectal cancer: A clue of systemic disease
    Young Il Kim, Jong Keon Jang, In Ja Park, Seong Ho Park, Jong Beom Kim, Jin-Hong Park, Tae Won Kim, Jun-Soo Ro, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
    Surgical Oncology.2020; 35: 174.     CrossRef
  • Transformation of Pathology Reports Into the Common Data Model With Oncology Module: Use Case for Colon Cancer
    Borim Ryu, Eunsil Yoon, Seok Kim, Sejoon Lee, Hyunyoung Baek, Soyoung Yi, Hee Young Na, Ji-Won Kim, Rong-Min Baek, Hee Hwang, Sooyoung Yoo
    Journal of Medical Internet Research.2020; 22(12): e18526.     CrossRef
Tumor immune response and immunotherapy in gastric cancer
Yoonjin Kwak, An Na Seo, Hee Eun Lee, Hye Seung Lee
J Pathol Transl Med. 2020;54(1):20-33.   Published online November 1, 2019
DOI: https://doi.org/10.4132/jptm.2019.10.08
  • 13,115 View
  • 722 Download
  • 57 Web of Science
  • 52 Crossref
AbstractAbstract PDF
Remarkable developments in immuno-oncology have changed the landscape of gastric cancer (GC) treatment. Because immunotherapy intervenes with tumor immune response rather than directly targeting tumor cells, it is important to develop a greater understanding of tumor immunity. This review paper summarizes the tumor immune reaction and immune escape mechanisms while focusing on the role of T cells and their co-inhibitory signals, such as the immune checkpoint molecules programmed death-1 and programmed deathligand 1 (PD-L1). This paper also describes past clinical trials of immunotherapy for patients with GC and details their clinical implications. Strong predictive markers are essential to improve response to immunotherapy. Microsatellite instability, Epstein-Barr virus, PD-L1 expression, and tumor mutational burden are now regarded as potent predictive markers for immunotherapy in patients with GC. Novel immunotherapy and combination therapy targeting new immune checkpoint molecules such as lymphocyte-activation gene 3, T cell immunoglobulin, and mucin domain containing-3, and indoleamine 2,3-dioxygenase have been suggested, and trials are ongoing to evaluate their safety and efficacy. Immunotherapy is an important treatment option for patients with GC and has great potential for improving patient outcome, and further research in immuno-oncology should be carried out.

Citations

Citations to this article as recorded by  
  • Ubiquilin-4 induces immune escape in gastric cancer by activating the notch signaling pathway
    Quan Jiang, Hao Chen, Shixin Zhou, Tao Zhu, Wenshuai Liu, Hao Wu, Yong Zhang, Fenglin Liu, Yihong Sun
    Cellular Oncology.2024; 47(1): 303.     CrossRef
  • Expression and prognostic value of APOBEC2 in gastric adenocarcinoma and its association with tumor-infiltrating immune cells
    Lipan Wei, Xiuqian Wu, Lan Wang, Ling Chen, Xuejun Wu, Tiantian Song, Yuanyuan Wang, Wenjun Chang, Aizhen Guo, Yongdong Niu, Haihua Huang
    BMC Cancer.2024;[Epub]     CrossRef
  • Identification and characterization of CLEC11A and its derived immune signature in gastric cancer
    Qing Zheng, Zhenqi Gong, Baizhi Li, Runzi Cheng, Weican Luo, Cong Huang, Huaiming Wang
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer
    Hao Yang, Xinyi Gou, Caizhen Feng, Yinli Zhang, Fan Chai, Nan Hong, Yingjiang Ye, Yi Wang, Bo Gao, Jin Cheng
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • A standardized pathology report for gastric cancer: 2nd edition
    Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
    Journal of Pathology and Translational Medicine.2023; 57(1): 1.     CrossRef
  • A Standardized Pathology Report for Gastric Cancer: 2nd Edition
    Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
    Journal of Gastric Cancer.2023; 23(1): 107.     CrossRef
  • Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
    Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im
    Journal of Gastric Cancer.2023; 23(1): 3.     CrossRef
  • Could Toll-like Receptor 2 Serve as Biomarker to Detect Advanced Gastric Cancer?
    Marek Majewski, Kamil Torres, Paulina Mertowska, Sebastian Mertowski, Izabela Korona-Głowniak, Jan Korulczyk, Witold Zgodziński, Ewelina Grywalska
    International Journal of Molecular Sciences.2023; 24(6): 5824.     CrossRef
  • Research Progress of Immunotherapy for Gastric Cancer
    Zhipeng Zhang, Ningning Liu, Mingyu Sun
    Technology in Cancer Research & Treatment.2023; 22: 153303382211505.     CrossRef
  • Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment
    Xinyi Shao, Jin Yin, Di Wang, Erjiong Huang, Yini Zhang, Jiani C. Yin, Chen Huang, Hao Wu, Xiaoli Wu
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Artificial Intelligence-Enabled Gastric Cancer Interpretations
    Mustafa Yousif, Liron Pantanowitz
    Surgical Pathology Clinics.2023; 16(4): 673.     CrossRef
  • The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer
    Jae Yeon Jang, Youngkyung Jeon, Sun Young Jeong, Sung Hee Lim, Won Ki Kang, Jeeyun Lee, Seung Tae Kim
    Journal of Gastric Cancer.2023; 23(3): 476.     CrossRef
  • Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer
    Moonsik Kim, Ji Yun Jeong, An Na Seo
    Diagnostics.2023; 13(17): 2782.     CrossRef
  • The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy
    Yuting Pan, Yue Ma, Guanghai Dai
    Nutrients.2023; 15(19): 4290.     CrossRef
  • Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE
    Kenichiro Furukawa, Keiichi Hatakeyama, Masanori Terashima, Takeshi Nagashima, Kenichi Urakami, Keiichi Ohshima, Akifumi Notsu, Takashi Sugino, Taisuke Yagi, Keiichi Fujiya, Satoshi Kamiya, Makoto Hikage, Yutaka Tanizawa, Etsuro Bando, Yae Kanai, Yasuto A
    Gastric Cancer.2022; 25(1): 138.     CrossRef
  • Immunotherapy for gastric cancer: a 2021 update
    Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, Nikolaos-Iasonas Kouris, George Papaxoinis, Michalis V Karamouzis, Anna Koumarianou, Dimitrios Schizas
    Immunotherapy.2022; 14(1): 41.     CrossRef
  • The immune microenvironment in gastric adenocarcinoma
    Yana Zavros, Juanita L. Merchant
    Nature Reviews Gastroenterology & Hepatology.2022; 19(7): 451.     CrossRef
  • Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer
    Raghad Khalid AL-Ishaq, Lenka Koklesova, Peter Kubatka, Dietrich Büsselberg
    Cancers.2022; 14(9): 2140.     CrossRef
  • An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma
    Xiaowen Zhao, Pingfan Wu, Dongling Liu, Changtian Li, Ling Xue, Zhe Liu, Meng Zhu, Jie Yang, Ziyi Chen, Yaling Li, Yali She, Kathiravan Srinivasan
    Journal of Healthcare Engineering.2022; 2022: 1.     CrossRef
  • RNA modification writers influence tumor microenvironment in gastric cancer and prospects of targeted drug therapy
    Peng Song, Sheng Zhou, Xiaoyang Qi, Yuwen Jiao, Yu Gong, Jie Zhao, Haojun Yang, Zhifen Qian, Jun Qian, Liming Tang
    Journal of Bioinformatics and Computational Biology.2022;[Epub]     CrossRef
  • Identification of the three subtypes and the prognostic characteristics of stomach adenocarcinoma: analysis of the hypoxia-related long non-coding RNAs
    Zehua Fan, Yanqun Wang, Rong Niu
    Functional & Integrative Genomics.2022; 22(5): 919.     CrossRef
  • Complete Response of High Microsatellite Instability Gastric Cancer and Synchronous Microsatellite Stability Rectal Cancer
    Zachary E Hunzeker, Pooja Bhakta, Sindusha R Gudipally, Sri Bharathi Kavuri, Rohit Venkatesan, Chukwuyejulumafor Nwanze
    Cureus.2022;[Epub]     CrossRef
  • Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression
    Yuhan Wei, Jianwei Zhang, Xueke Fan, Zhi Zheng, Xiaoyue Jiang, Dexi Chen, Yuting Lu, Yingrui Li, Miao Wang, Min Hu, Qi Du, Liuting Yang, Hongzhong Li, Yi Xiao, Yongfu Li, Jiangtao Jin, Deying Wang, Xiangliang Yuan, Qin Li
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Tumor vessel normalization and immunotherapy in gastric cancer
    Xianzhe Yu, Shan He, Jian Shen, Qiushi Huang, Peng Yang, Lin Huang, Dan Pu, Li Wang, Lu Li, Jinghua Liu, Zelong Liu, Lingling Zhu
    Therapeutic Advances in Medical Oncology.2022; 14: 175883592211101.     CrossRef
  • FN1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers
    Han Wang, Junchang Zhang, Huan Li, Hong Yu, Songyao Chen, Shuhao Liu, Changhua Zhang, Yulong He
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Molecular Pathology of Gastric Cancer
    Moonsik Kim, An Na Seo
    Journal of Gastric Cancer.2022; 22(4): 264.     CrossRef
  • Bioinformatics Analysis and Structure of Gastric Cancer Prognosis Model Based on Lipid Metabolism and Immune Microenvironment
    Yongzhi Chen, Hongjun Yuan, Qian Yu, Jianyu Pang, Miaomiao Sheng, Wenru Tang
    Genes.2022; 13(9): 1581.     CrossRef
  • Clinical implications of interleukins-31, 32, and 33 in gastric cancer
    Qing-Hua Liu, Ji-Wei Zhang, Lei Xia, Steven G Wise, Brett David Hambly, Kun Tao, Shi-San Bao
    World Journal of Gastrointestinal Oncology.2022; 14(9): 1808.     CrossRef
  • Microbiota and the Immune System—Actors in the Gastric Cancer Story
    Marek Majewski, Paulina Mertowska, Sebastian Mertowski, Konrad Smolak, Ewelina Grywalska, Kamil Torres
    Cancers.2022; 14(15): 3832.     CrossRef
  • Bioinformatics and Experimental Analyses Reveal MAP4K4 as a Potential Marker for Gastric Cancer
    Junping Zhang, Xiaoping Cai, Weifeng Cui, Zheng Wei
    Genes.2022; 13(10): 1786.     CrossRef
  • Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors
    Shuang Ma, Fei Chen
    Pathology - Research and Practice.2022; 238: 154110.     CrossRef
  • High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer
    Shouyu Ke, Feng Xie, Yixian Guo, Jieqiong Chen, Zeyu Wang, Yimeng Yu, Haigang Geng, Danhua Xu, Xu Liu, Xiang Xia, Fengrong Yu, Chunchao Zhu, Zizhen Zhang, Gang Zhao, Bin Li, Wenyi Zhao
    iScience.2022; 25(12): 105529.     CrossRef
  • Characteristics of Adenosine-to-Inosine RNA editing-based subtypes and novel risk score for the prognosis and drug sensitivity in stomach adenocarcinoma
    Jingjing Pan, Xinyuan Gu, Jing Luo, Xinye Qian, Qiang Gao, Tianjie Li, Longying Ye, Chenlu Li
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Inhibition of NF‐κB is required for oleanolic acid to downregulate PD‐L1 by promoting DNA demethylation in gastric cancer cells
    Xirong Lu, Yuyi Li, Wei Yang, Minghao Tao, Yanmiao Dai, Jinkang Xu, Qianfei Xu
    Journal of Biochemical and Molecular Toxicology.2021;[Epub]     CrossRef
  • Prognostic Value of C-Reactive Protein to Albumin Ratio in Gastric Cancer: A Meta-Analysis
    Liang Yue, Yi Lu, Yulin Li, Yilin Wang
    Nutrition and Cancer.2021; 73(10): 1864.     CrossRef
  • Immunogenic characteristics of microsatellite instability‐low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses
    Yu Imamura, Tasuku Toihata, Ikumi Haraguchi, Yoko Ogata, Manabu Takamatsu, Aya Kuchiba, Norio Tanaka, Osamu Gotoh, Seiichi Mori, Yuichiro Nakashima, Eiji Oki, Masaki Mori, Yoshinao Oda, Kenichi Taguchi, Manabu Yamamoto, Masaru Morita, Naoya Yoshida, Hideo
    International Journal of Cancer.2021; 148(5): 1260.     CrossRef
  • Two Similar Signatures for Predicting the Prognosis and Immunotherapy Efficacy of Stomach Adenocarcinoma Patients
    Taohua Yue, Shuai Zuo, Jing Zhu, Shihao Guo, Zhihao Huang, Jichang Li, Xin Wang, Yucun Liu, Shanwen Chen, Pengyuan Wang
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Tumor microenvironment characterization in stage IV gastric cancer
    Feng Yang, Zhenbao Wang, Xianxue Zhang
    Bioscience Reports.2021;[Epub]     CrossRef
  • E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer
    Hui Li, Shufen Zhao, Liwei Shen, Peige Wang, Shihai Liu, Yingji Ma, Zhiwei Liang, Gongjun Wang, Jing Lv, Wensheng Qiu
    Aging.2021; 13(10): 13626.     CrossRef
  • Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer
    S. H. Petersen, L. F. Kua, S. Nakajima, W. P. Yong, K. Kono
    Scientific Reports.2021;[Epub]     CrossRef
  • Establishment of an Immune Cell Infiltration Score to Help Predict the Prognosis and Chemotherapy Responsiveness of Gastric Cancer Patients
    Quan Jiang, Jie Sun, Hao Chen, Chen Ding, Zhaoqing Tang, Yuanyuan Ruan, Fenglin Liu, Yihong Sun
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Microsatellite instability in Gastric Cancer: Between lights and shadows
    Elisabetta Puliga, Simona Corso, Filippo Pietrantonio, Silvia Giordano
    Cancer Treatment Reviews.2021; 95: 102175.     CrossRef
  • Survival-associated alternative splicing events interact with the immune microenvironment in stomach adenocarcinoma
    Zai-Sheng Ye, Miao Zheng, Qin-Ying Liu, Yi Zeng, Sheng-Hong Wei, Yi Wang, Zhi-Tao Lin, Chen Shu, Qiu-Hong Zheng, Lu-Chuan Chen
    World Journal of Gastroenterology.2021; 27(21): 2871.     CrossRef
  • Immunotherapy of gastric cancer: Past, future perspective and challenges
    Jun Xie, Liping Fu, Li Jin
    Pathology - Research and Practice.2021; 218: 153322.     CrossRef
  • Clinicopathologic and Prognostic Association of GRP94 Expression in Colorectal Cancer with Synchronous and Metachronous Metastases
    Sumi Yun, Sukmook Lee, Ho-Young Lee, Hyeon Jeong Oh, Yoonjin Kwak, Hye Seung Lee
    International Journal of Molecular Sciences.2021; 22(13): 7042.     CrossRef
  • Injectable shear-thinning polylysine hydrogels for localized immunotherapy of gastric cancer through repolarization of tumor-associated macrophages
    Yan Yang, Yang Yang, Meili Chen, Jianquan Chen, Jinyan Wang, Yajun Ma, Hanqing Qian
    Biomaterials Science.2021; 9(19): 6597.     CrossRef
  • Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer
    Sizhe Hu, Xiaokang Zhao, Feng Qian, Cancan Jin, Kaishun Hou, Tao Huang
    Computational and Mathematical Methods in Medicine.2021; 2021: 1.     CrossRef
  • Comprehensive Analysis to Identify MAGEA3 Expression Correlated With Immune Infiltrates and Lymph Node Metastasis in Gastric Cancer
    Jinji Jin, Jianxin Tu, Jiahuan Ren, Yiqi Cai, Wenjing Chen, Lifang Zhang, Qiyu Zhang, Guanbao Zhu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Effect of P2X7 receptor on tumorigenesis and its pharmacological properties
    Wen-jun Zhang, Ce-gui Hu, Zheng-ming Zhu, Hong-liang Luo
    Biomedicine & Pharmacotherapy.2020; 125: 109844.     CrossRef
  • Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
    Byung Woog Kang, Ian Chau
    ESMO Open.2020; 5(4): e000791.     CrossRef
  • Is ramucirumab still the only second-line treatment in metastatic gastric cancer?
    Khalil El Gharib, Hampig Raphael Kourie
    Pharmacogenomics.2020; 21(17): 1203.     CrossRef
  • Deep Learning Predicts Underlying Features on Pathology Images with Therapeutic Relevance for Breast and Gastric Cancer
    Renan Valieris, Lucas Amaro, Cynthia Aparecida Bueno de Toledo Osório, Adriana Passos Bueno, Rafael Andres Rosales Mitrowsky, Dirce Maria Carraro, Diana Noronha Nunes, Emmanuel Dias-Neto, Israel Tojal da Silva
    Cancers.2020; 12(12): 3687.     CrossRef
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
J Pathol Transl Med. 2020;54(1):34-44.   Published online November 6, 2019
DOI: https://doi.org/10.4132/jptm.2019.11.03
  • 18,397 View
  • 1,048 Download
  • 101 Web of Science
  • 102 Crossref
AbstractAbstract PDF
Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed breast cancer in pathology. Currently, HER2 immunohistochemistry (IHC) is used for a screening test, and in situ hybridization is used as a confirmation test for HER2 IHC equivocal cases. Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer. During HER2 interpretation, some pitfalls such as intratumoral HER2 heterogeneity and increase in chromosome enumeration probe 17 signals may lead to inaccurate assessment of HER2 status. Moreover, HER2 status can be altered after neoadjuvant chemotherapy or during metastatic progression, due to biologic or methodologic issues. This review addresses recent updates of ASCO/CAP guidelines and factors complicating in the interpretation of HER2 status in breast cancers.

Citations

Citations to this article as recorded by  
  • Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
    Mariia Ivanova, Francesca Maria Porta, Marianna D’Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Elena Guerini-Rocco, Giuseppe Curigliano, Giuseppe Viale, Nicola Fusco
    Virchows Archiv.2024; 484(1): 3.     CrossRef
  • Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing–Based Comprehensive Tumor Profiling in Liquid Biopsy Samples
    Johannes Harter, Eleonora Buth, Janina Johaenning, Florian Battke, Maria Kopp, Henning Zelba, Martin Schulze, Jiri Koedding, Saskia Biskup
    The Journal of Molecular Diagnostics.2024; 26(1): 61.     CrossRef
  • Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
    Camille Suydam, Fairouz Chibane, Nicole Brown, Madeleine Schlafly, Alicia H. Arnold, Intisar Ghleilib, Melissa Easley, Joseph White
    Annals of Surgical Oncology.2024; 31(1): 376.     CrossRef
  • Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis
    Huiyue Li, Jennifer K. Plichta, Kan Li, Yizi Jin, Samantha M. Thomas, Fei Ma, Li Tang, Qingyi Wei, You-Wen He, Qichen Chen, Yuanyuan Guo, Yueping Liu, Jian Zhang, Sheng Luo
    Breast Cancer Research and Treatment.2024; 204(1): 89.     CrossRef
  • Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
    Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tol
    npj Breast Cancer.2024;[Epub]     CrossRef
  • Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
    Melissa Yuwono Tjota, Jeremy P Segal, Peng Wang
    The Journal of Applied Laboratory Medicine.2024; 9(1): 76.     CrossRef
  • High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles
    Sanathana Konugolu Venkata Sekar, Hui Ma, Katarzyna Komolibus, Gokhan Dumlupinar, Matthias J. Mickert, Krzysztof Krawczyk, Stefan Andersson-Engels
    Biomedical Optics Express.2024; 15(2): 900.     CrossRef
  • HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
    Ximena Baez-Navarro, Mieke R. van Bockstal, Agnes Jager, Carolien H.M. van Deurzen
    Pathology.2024; 56(3): 334.     CrossRef
  • Fast-tracking drug development with biomarkers and companion diagnostics
    Noreen McBrearty, Devika Bahal, Suso Platero
    Journal of Cancer Metastasis and Treatment.2024;[Epub]     CrossRef
  • Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression
    Gary Tozbikian, Savitri Krishnamurthy, Marilyn M. Bui, Michael Feldman, David G. Hicks, Shabnam Jaffer, Thaer Khoury, Shi Wei, Hannah Wen, Paula Pohlmann
    Archives of Pathology & Laboratory Medicine.2024; 148(2): 242.     CrossRef
  • Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
    Eliya Farah, Chantelle Carbonell, Devon J. Boyne, Darren R. Brenner, Jan-Willem Henning, Daniel Moldaver, Simran Shokar, Winson Y. Cheung
    Cancers.2024; 16(3): 518.     CrossRef
  • Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma
    Yoga S. Narwadkar, Rahul V. Parghane, Sudeep Sahu, Sangita Lad, Kamal Deep, Gaurav Wanage, Tejal Suralkar, Sharmila Banerjee, Sudeep Gupta, Sandip Basu, Rajendra A. Badwe
    Clinical Nuclear Medicine.2024; 49(4): e149.     CrossRef
  • Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration
    Cristina Díaz del Arco, María Jesús Fernández Aceñero, Luis Ortega Medina
    International Journal of Molecular Sciences.2024; 25(5): 2649.     CrossRef
  • The combined immunohistochemical expression of AMBRA1 and SQSTM1 identifies patients with poorly differentiated cutaneous squamous cell carcinoma at risk of metastasis: A proof of concept study
    Michael H. Alexander, William J. Cousins, Tom Ewen, Andrew P. South, Penny Lovat, Niki Stefanos
    Journal of Cutaneous Pathology.2024;[Epub]     CrossRef
  • Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry
    Jing Wang, Esther Yoon, Savitri Krishnamurthy
    Annals of Diagnostic Pathology.2024; 70: 152288.     CrossRef
  • Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial
    Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao
    Breast Cancer Research.2024;[Epub]     CrossRef
  • Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients
    Yibo Chen, Tianyi Zhang, Rui Zhang, Xuchen Cao
    Cancer Biotherapy and Radiopharmaceuticals.2024;[Epub]     CrossRef
  • Clinicopathological and prognostic significance of VEGF, PDGF-B, and HER2/neu expression in gallbladder cancer
    Pooja Shukla, Kumudesh Mishra, Ratnakar Shukla, Ruchira Vishwakarma, Niraj Kumari, Narendra Krishnani, Anu Behari, Vinay K. Kapoor
    Journal of Cancer Research and Therapeutics.2024; 20(1): 349.     CrossRef
  • Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
    G. Curigliano, R. Dent, H. Earle, S. Modi, P. Tarantino, G. Viale, S.M. Tolaney
    ESMO Open.2024; 9(4): 102989.     CrossRef
  • Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status
    Sei Na, Milim Kim, Yujun Park, Hyun Jung Kwon, Hee-Chul Shin, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, So Yeon Park
    Breast Cancer.2024;[Epub]     CrossRef
  • Surgical Management of the Axilla in HR+/HER2– Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database
    Vayda R. Barker, Samer A. Naffouje, Melissa A. Mallory, Susan A. Hoover, Christine Laronga
    Annals of Surgical Oncology.2023; 30(13): 8371.     CrossRef
  • Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer
    Yuan Guo, Xiaotong Xie, Wenjie Tang, Siyi Chen, Mingyu Wang, Yaheng Fan, Chuxuan Lin, Wenke Hu, Jing Yang, Jialin Xiang, Kuiming Jiang, Xinhua Wei, Bingsheng Huang, Xinqing Jiang
    European Radiology.2023; 34(2): 899.     CrossRef
  • Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
    Lan Deng, Le Zhao, Lifen Liu, Haomin Huang
    Open Life Sciences.2023;[Epub]     CrossRef
  • HER2-low expression in patients with advanced or metastatic solid tumors
    B. Uzunparmak, C. Haymaker, G. Raso, S. Masciari, L. Wang, H. Lin, A. Gorur, B. Kirby, A.-M. Cimo, A. Kennon, Q. Ding, G. Urschel, Y. Yuan, G. Feng, Y. Rizvi, A. Hussain, C. Zhu, P. Kim, G. Abbadessa, V. Subbiah, T.A. Yap, J. Rodon, S.A. Piha-Paul, F. Mer
    Annals of Oncology.2023; 34(11): 1035.     CrossRef
  • Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines
    Son H. Pham, Lyn R. Griffiths, Rachel K. Okolicsanyi, Larisa M. Haupt
    Data in Brief.2023; 46: 108880.     CrossRef
  • Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
    Christiane Palm, Catherine E. Connolly, Regina Masser, Barbara Padberg Sgier, Eva Karamitopoulou, Quentin Simon, Beata Bode, Marianne Tinguely
    Diagnostics.2023; 13(1): 168.     CrossRef
  • Gene amplification mutations originate prior to selective stress in Acinetobacter baylyi
    Jennifer A Herrmann, Agata Koprowska, Tesa J Winters, Nancy Villanueva, Victoria D Nikityuk, Feini Pek, Elizabeth M Reis, Constancia Z Dominguez, Daniel Davis, Eric McPherson, Staci R Rocco, Cynthia Recendez, Shyla M Difuntorum, Kelly Faeth, Mario D Lopez
    G3.2023;[Epub]     CrossRef
  • Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology
    Jie Wang, Robert Dallmann, Renquan Lu, Jing Yan, Jérôme Charmet
    ACS Sensors.2023; 8(3): 1200.     CrossRef
  • Single-cell HER2 quantification via instant signal amplification in microdroplets
    Xiaoxian Liu, Yifan Zhu, Caoxin Li, Yanyun Fang, Jinna Chen, Fei Xu, Yanqing Lu, Perry Ping Shum, Ying Liu, Guanghui Wang
    Analytica Chimica Acta.2023; 1251: 340976.     CrossRef
  • Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
    Daniela Miladinova
    Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
  • CORRELATION BETWEEN DIFFERENT CLINICOPATHOLOGICAL PARAMETERS AND MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA IN SOUTH REGION OF IRAQ
    Yassir Alaa Muhammed Hassan Shubbar
    Wiadomości Lekarskie.2023; 76(1): 97.     CrossRef
  • Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
    Elham Sajjadi, Elena Guerini-Rocco, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Mariia Ivanova, Nicola Fusco
    Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
  • Protective Effect of HER2 Gene Polymorphism rs24537331 in the Outcome of Canine Mammary Tumors
    Ana Canadas-Sousa, Marta Santos, Patrícia Dias-Pereira
    Animals.2023; 13(8): 1384.     CrossRef
  • Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
    Jin Wang, Dongying Liao, Xuemin Zhang, Changhong Miao, Kuang Chen
    Breast Cancer: Targets and Therapy.2023; Volume 15: 281.     CrossRef
  • HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
    Marina Popović, Tajana Silovski, Marija Križić, Natalija Dedić Plavetić
    International Journal of Molecular Sciences.2023; 24(9): 8206.     CrossRef
  • HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
    Aditya Bardia, Giuseppe Viale
    Targeted Oncology.2023; 18(3): 313.     CrossRef
  • Histopathological and immunohistochemical analysis of predictive and prognostic markers in spontaneous canine mammary cancer
    Vladimír Tancoš, Marcel Kovalik, Martin Levkut, Martina Bobrovská, Petra Kolenčíková, Ľubomír Straka, Zuzana Ševčíková, Ondřej Škor, Martina Antošová, Lukáš Plank, Keith L. Thoday
    Acta Veterinaria Brno.2023; 92(2): 143.     CrossRef
  • Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study
    Timothy Qi, Yanguang Cao
    European Journal of Pharmaceutical Sciences.2023; 186: 106467.     CrossRef
  • The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis
    Yakup Ergun, Baran Akagunduz, Cengiz Karacin, Sema Turker, Gokhan Ucar
    Clinical Breast Cancer.2023; 23(6): 567.     CrossRef
  • Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study
    Hao Wang, Hailing Cao, Zhiyun Guo
    Oncology Letters.2023;[Epub]     CrossRef
  • Identification of novel chemical scaffolds against kinase domain of cancer causing human epidermal growth factor receptor 2: a systemic chemoinformatic approach
    Faris Alrumaihi
    Journal of Biomolecular Structure and Dynamics.2023; : 1.     CrossRef
  • Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
    Feng Ye, Saikat Dewanjee, Yuehua Li, Niraj Kumar Jha, Zhe-Sheng Chen, Ankush Kumar, Vishakha, Tapan Behl, Saurabh Kumar Jha, Hailin Tang
    Molecular Cancer.2023;[Epub]     CrossRef
  • Weakly supervised bilayer convolutional network in segmentation of HER2 related cells to guide HER2 targeted therapies
    Ching-Wei Wang, Kun-Lin Lin, Hikam Muzakky, Yi-Jia Lin, Tai-Kuang Chao
    Computerized Medical Imaging and Graphics.2023; 108: 102270.     CrossRef
  • Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
    Francesca Maria Porta, Elham Sajjadi, Konstantinos Venetis, Chiara Frascarelli, Giulia Cursano, Elena Guerini-Rocco, Nicola Fusco, Mariia Ivanova
    Journal of Personalized Medicine.2023; 13(7): 1176.     CrossRef
  • HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?
    Reena Dhansukh Mohanlal, Nikki Bouwer, Pascale Willem
    Applied Immunohistochemistry & Molecular Morphology.2023; 31(8): 555.     CrossRef
  • Discordance of HER2 Expression and/or Amplification on Repeat Testing
    Timothy P. DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press, Sarina A. Piha-Paul, Ecaterina E. Dumbrava, Funda Meric-Bernstam
    Molecular Cancer Therapeutics.2023; 22(8): 976.     CrossRef
  • Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
    Mariausilia Franchina, Cristina Pizzimenti, Vincenzo Fiorentino, Maurizio Martini, Giuseppina Rosaria Rita Ricciardi, Nicola Silvestris, Antonio Ieni, Giovanni Tuccari
    International Journal of Molecular Sciences.2023; 24(16): 12795.     CrossRef
  • Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
    Kuikui Jiang, Danyang Zhou, Fei Xu, Wen Xia, Qiufan Zheng, Qianyi Lu, Rongzhen Luo, Ruoxi Hong, Shusen Wang
    BMC Cancer.2023;[Epub]     CrossRef
  • Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization
    Ahmad Najafi, Reza Valadan, Hossein Asgarian-Omran, Alireza Rafiei, Mohsen Tehrani
    International Immunopharmacology.2023; 124: 110999.     CrossRef
  • Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites
    Imane Eliahiai, Mohammed Eljiar, Sanae Chaib, Jinane KHarmoum, Mariame Chraïbi
    Bulletin du Cancer.2023; 110(12): 1301.     CrossRef
  • HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method
    Beate Alinger-Scharinger, Cornelia Kronberger, Georg Hutarew, Wolfgang Hitzl, Roland Reitsamer, Klaassen-Federspiel Frederike, Martina Hager, Thorsten Fischer, Karl Sotlar, Heidi Jaksch-Bogensperger
    Virchows Archiv.2023;[Epub]     CrossRef
  • Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS)
    Jean-Louis Merlin, Marie Husson, Nassim Sahki, Pauline Gilson, Vincent Massard, Alexandre Harlé, Agnès Leroux
    Biomedicines.2023; 11(12): 3164.     CrossRef
  • Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer
    Neda Shahbazi, Rouholah Zare-Dorabei, Seyed Morteza Naghib
    ACS Biomaterials Science & Engineering.2022; 8(2): 871.     CrossRef
  • A highly sensitive nanobiosensor based on aptamer-conjugated graphene-decorated rhodium nanoparticles for detection of HER2-positive circulating tumor cells
    Mahdi Sadeghi, Soheila Kashanian, Seyed Morteza Naghib, Esfandyar Askari, Fateme Haghiralsadat, Davood Tofighi
    Nanotechnology Reviews.2022; 11(1): 793.     CrossRef
  • Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
    Carrie S. Wynn, Shou-Ching Tang
    Cancer and Metastasis Reviews.2022; 41(1): 193.     CrossRef
  • Electroanalytical overview: screen-printed electrochemical sensing platforms for the detection of vital cardiac, cancer and inflammatory biomarkers
    Robert D. Crapnell, Alejandro Garcia-Miranda Ferrari, Nina C. Dempsey, Craig E. Banks
    Sensors & Diagnostics.2022; 1(3): 405.     CrossRef
  • FTO genotype was associated with breast cancer in HER2 negative patients
    Fateme Montazeri, Hossein Hatami, Soroor Fathi, Naeemeh Hasanpour Ardekanizadeh, Fatemeh Bourbour, Samira Rastgoo, Fatemeh Shafiee, Mohammad Esmail Akbari, Maryam Gholamalizadeh, Seyed Alireza Mosavi Jarrahi, Saeid Doaei
    Clinical Nutrition ESPEN.2022; 49: 495.     CrossRef
  • Breast Cancer Human Epidermal Growth Factor Receptor 2 mRNA Molecular Testing Compared to Immunohistochemistry with Correlation to Neoadjuvant Therapy Response
    Mahmoud Behairy, Samia Mohamed Gabal, Mohamed Sherif Negm
    Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 352.     CrossRef
  • Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review
    Noortje Verschoor, Teoman Deger, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W.M. Martens
    Cancer Treatment Reviews.2022; 106: 102384.     CrossRef
  • RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients
    Hui Liu, Xiaoyan Hu, Lingyun Wang, Tao Du, Jing Feng, Ming Li, Lei Liu, Xiaofang Liu
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Use of Radionuclide-Based Imaging Methods in Breast Cancer
    Betül Altunay, Agnieszka Morgenroth, Felix M. Mottaghy
    Seminars in Nuclear Medicine.2022; 52(5): 561.     CrossRef
  • Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer
    Li Wang, Lei Yu, Jian Shi, Feng Li, Caiyu Zhang, Haotian Xu, Xiangzhe Yin, Lixia Wang, Shihua Lin, Anastasiia Litvinova, Yanyan Ping, Shangwei Ning, Hongying Zhao
    Scientific Reports.2022;[Epub]     CrossRef
  • Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
    Anastasia Alataki, Mitch Dowsett
    Endocrine-Related Cancer.2022; 29(8): R105.     CrossRef
  • The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
    Olga D. Bragina, Sergei M. Deyev, Vladimir I. Chernov, Vladimir M. Tolmachev
    Acta Naturae.2022; 14(2): 4.     CrossRef
  • Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations
    Stephanie E. Siegmund, Danielle K. Manning, Phani K. Davineni, Fei Dong
    Modern Pathology.2022; 35(10): 1458.     CrossRef
  • Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
    Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann, Khalil Zaman
    The Breast.2022; 66: 145.     CrossRef
  • Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
    Fang Lu, Tingting Zhou, Yan Liu, Liying Song, Bin Zhang, Yuyan Li, Sorayouth Chumnanvej
    Contrast Media & Molecular Imaging.2022; 2022: 1.     CrossRef
  • High sensitivity label-free detection of HER2 using an Al–GaN/GaN high electron mobility transistor-based biosensor
    Shivanshu Mishra, Pharyanshu Kachhawa, Amber Kumar Jain, Rajiv Ranjan Thakur, Nidhi Chaturvedi
    Lab on a Chip.2022; 22(21): 4129.     CrossRef
  • Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
    B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel
    South Asian Journal of Cancer.2022; 11(04): 281.     CrossRef
  • S‑phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma
    António Pinto, João Matos, Teresa Pereira, Giovani Silva, Saudade André
    Oncology Letters.2022;[Epub]     CrossRef
  • Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling
    Alina Batzilla, Junyan Lu, Jarno Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang Huber, James Gallo
    PLOS Computational Biology.2022; 18(8): e1010438.     CrossRef
  • Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
    O. D. Bragina, V. I. Chernov, S. M. Deyev, V. M. Tolmachev
    Bulletin of Siberian Medicine.2022; 21(3): 132.     CrossRef
  • Molecular Pathology of Gastric Cancer
    Moonsik Kim, An Na Seo
    Journal of Gastric Cancer.2022; 22(4): 264.     CrossRef
  • Loss of NECTIN1 triggers melanoma dissemination upon local IGF1 depletion
    Julien Ablain, Amira Al Mahi, Harriet Rothschild, Meera Prasad, Sophie Aires, Song Yang, Maxim E. Dokukin, Shuyun Xu, Michelle Dang, Igor Sokolov, Christine G. Lian, Leonard I. Zon
    Nature Genetics.2022; 54(12): 1839.     CrossRef
  • Advanced diagnosis technologies for HER2 breast cancer markers
    Mengxue Zhang
    Highlights in Science, Engineering and Technology.2022; 14: 44.     CrossRef
  • An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
    Aleix Prat, Aditya Bardia, Giuseppe Curigliano, M. Elizabeth H. Hammond, Sibylle Loibl, Sara M. Tolaney, Giuseppe Viale
    JAMA Oncology.2022; 8(11): 1676.     CrossRef
  • Development of T-cell engagers selective for cells co-expressing two antigens
    Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson, Nicholas J. Agard
    mAbs.2022;[Epub]     CrossRef
  • The clinical significance of HER2 expression in DCIS
    Ioanna Akrida, Francesk Mulita
    Medical Oncology.2022;[Epub]     CrossRef
  • Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
    Rachel Occhiogrosso Abelman, Arielle Medford, Laura Spring, Aditya Bardia
    The Cancer Journal.2022; 28(6): 423.     CrossRef
  • The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
    Ugur Gezer, Abel J. Bronkhorst, Stefan Holdenrieder
    Diagnostics.2022; 12(12): 3042.     CrossRef
  • Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
    Systematic Reviews.2022;[Epub]     CrossRef
  • Interactions dietary components with expression level of breast cancer-related genes
    Fatemeh Bourbour, Azam Pourtaheri, Khadijeh Abbasi, Naeemeh Hasanpour Ardekanizadeh, Maryam Gholamalizadeh, Azadeh Hajipour, Sepideh Abdollahi, Seyedeh Elaheh Bagheri, Mina Ahmadzadeh, Saeid Doaei, Arezoo Haghighian
    Egyptian Journal of Medical Human Genetics.2022;[Epub]     CrossRef
  • HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
    Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler, Felix M. Mottaghy
    European Journal of Nuclear Medicine and Molecular Imaging.2021; 48(5): 1371.     CrossRef
  • Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
    Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart
    Cancer Treatment Reviews.2021; 99: 102229.     CrossRef
  • Histologic Patterns of Cutaneous Metastases of Breast Carcinoma: A Clinicopathologic Study of 232 Cases
    Shira Ronen, David Suster, Wei-Shen Chen, Natali Ronen, Sri Krishna C. Arudra, Celestine Trinidad, Doina Ivan, Victor G. Prieto, Saul Suster
    The American Journal of Dermatopathology.2021; 43(6): 401.     CrossRef
  • Standardized pathology report for breast cancer
    Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
    Journal of Pathology and Translational Medicine.2021; 55(1): 1.     CrossRef
  • The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine
    R. Bonfiglio, M.L. Di Pietro
    Seminars in Cancer Biology.2021; 72: 11.     CrossRef
  • The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study
    Yu-Xin Wang, Feng-Lian Li, Li-Xin Du, Jun-Fang Liu, Li-Gang Huo, Shu-Qing Li, Bin Tian
    Cancer Management and Research.2021; Volume 13: 6123.     CrossRef
  • Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker
    A. Fernández Asensio, M. Corte-Rodríguez, J. Bettmer, L.M. Sierra, M. Montes-Bayón, E. Blanco- González
    Talanta.2021; 235: 122773.     CrossRef
  • Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer
    Lingzhou Zhao, Changcun Liu, Yan Xing, Jin He, Jim O’Doherty, Wenhua Huang, Jinhua Zhao
    Molecular Pharmaceutics.2021; 18(9): 3616.     CrossRef
  • WITHDRAWN: Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
    Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
    Bulletin du Cancer.2021;[Epub]     CrossRef
  • Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
    Emad A. Rakha, Islam M. Miligy, Cecily M. Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchiò, Michael S. Toss, Grace Gallagy, Ciara Murray, Janice Walshe, Ayaka Katayama, Karim Eldib, Nahla Badr, Bruce Tanchel, Rebecca Millican-Slater, Colin Purd
    British Journal of Cancer.2021; 124(11): 1836.     CrossRef
  • Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes
    Catherine L. Wetzel, Thomas L. Sutton, Stuart Gardiner, Maryam Farinola, Nathalie Johnson, Jennifer R. Garreau
    Journal of Surgical Oncology.2021; 124(8): 1224.     CrossRef
  • Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
    Lun Li, Min Chen, Shuyue Zheng, Hanlu Li, Weiru Chi, Bingqiu Xiu, Qi Zhang, Jianjing Hou, Jia Wang, Jiong Wu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • tRNA‐derived fragments: tRF‐Gly‐CCC‐046, tRF‐Tyr‐GTA‐010 and tRF‐Pro‐TGG‐001 as novel diagnostic biomarkers for breast cancer
    Yue Zhang, Zhao Bi, Xiaohan Dong, Miao Yu, Kangyu Wang, Xingguo Song, Li Xie, Xianrang Song
    Thoracic Cancer.2021; 12(17): 2314.     CrossRef
  • Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
    L. De Cock, J. Heylen, A. Wildiers, K. Punie, A. Smeets, C. Weltens, P. Neven, J. Billen, A. Laenen, H. Wildiers
    ESMO Open.2021; 6(4): 100203.     CrossRef
  • Standardized Pathology Report for Breast Cancer
    Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
    Journal of Breast Cancer.2021; 24(1): 1.     CrossRef
  • Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
    Jin-xiu Zhong, Yun-yuan Kong, Rong-guang Luo, Guo-jin Xia, Wen-xing He, Xue-zhong Chen, Wei-wei Tan, Qing-jie Chen, Yu-yin Huang, Yan-xing Guan
    Journal of Translational Medicine.2021;[Epub]     CrossRef
  • Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
    Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
    Bulletin du Cancer.2021; 108(11): 11S8.     CrossRef
  • HER2 alterations in non-small-cell lung cancer – Druggable or undruggable?
    SureshKumar Bondili, Ravindra Nandhana, Vanita Noronha, Swayamprabha Pawar, Nandini Menon, Omshree Shetty, Anuradha Chougule, Abhishek Mahajan, Rajiv Kumar, VijayM Patil, Amit Joshi, Kumar Prabhash
    Cancer Research, Statistics, and Treatment.2021; 4(2): 374.     CrossRef
  • UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer
    Evgenii L. Guryev, Anita S. Smyshlyaeva, Natalia Y. Shilyagina, Evgeniya A. Sokolova, Samah Shanwar, Alexey B. Kostyuk, Alexander V. Lyubeshkin, Alexey A. Schulga, Elena V. Konovalova, Quan Lin, Indrajit Roy, Irina V. Balalaeva, Sergey M. Deyev, Andrei V.
    Molecules.2020; 25(18): 4302.     CrossRef
  • Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
    Min Chong Kim, Su Hwan Kang, Jung Eun Choi, Young Kyung Bae
    Journal of Breast Cancer.2020; 23(5): 484.     CrossRef
Molecular characteristics of meningiomas
Young Suk Lee, Youn Soo Lee
J Pathol Transl Med. 2020;54(1):45-63.   Published online January 15, 2020
DOI: https://doi.org/10.4132/jptm.2019.11.05
  • 13,855 View
  • 560 Download
  • 31 Web of Science
  • 34 Crossref
AbstractAbstract PDF
Meningioma is the most common primary intracranial tumor in adults. The grading of meningioma is based on World Health Organization criteria, which rely on histopathological features alone. This grading system is unable to conclusively predict the clinical behavior of these tumors (i.e., recurrence or prognosis in benign or atypical grades). Advances in molecular techniques over the last decade that include genomic and epigenomic data associated with meningiomas have been used to identify genetic biomarkers that can predict tumor behavior. This review summarizes the molecular characteristics of meningioma using genetic and epigenetic biomarkers. Molecular alterations that can predict meningioma behavior may be integrated into the upcoming World Health Organization grading system.

Citations

Citations to this article as recorded by  
  • The Natural History and Treatment of Meningiomas: An Update
    Arsene Daniel Nyalundja, Fabrice Mugisha, Claire Karekezi
    Seminars in Neurology.2024; 44(01): 001.     CrossRef
  • Epidemiology, Genetics, and DNA Methylation Grouping of Hyperostotic Meningiomas
    Gray Umbach, Edwina B. Tran, Charlotte D. Eaton, Abrar Choudhury, Ramin Morshed, Javier E. Villanueva-Meyer, Philip V. Theodosopoulos, Stephen T. Magill, Michael W. McDermott, David R. Raleigh, Ezequiel Goldschmidt
    Operative Neurosurgery.2024;[Epub]     CrossRef
  • DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups
    Jyotsna Singh, Ravi Sharma, Nidhi Shukla, Priya Narwal, Amit Katiyar, Swati Mahajan, Saumya Sahu, Ajay Garg, Mehar C. Sharma, Ashish Suri, Chitra sarkar, Vaishali Suri
    Journal of Neuro-Oncology.2023; 161(2): 339.     CrossRef
  • Spinal meningiomas, from biology to management - A literature review
    Nicolas Serratrice, Imène Lameche, Christian Attieh, Moussa A Chalah, Joe Faddoul, Bilal Tarabay, Rabih Bou-Nassif, Youssef Ali, Joseph G Mattar, François Nataf, Samar S Ayache, Georges N Abi Lahoud
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression
    Sarah A Cain, Bernard Pope, Stefano Mangiola, Theo Mantamadiotis, Katharine J Drummond
    BMC Cancer.2023;[Epub]     CrossRef
  • Actualización sobre el meningioma: correlación clínico-radiológica y radio-patológica
    A. Navarro-Ballester, M. Aleixandre-Barrachina, S.F. Marco-Doménech
    Radiología.2023; 65(5): 458.     CrossRef
  • SMARCE1-related meningiomas: A clear example of cancer predisposing syndrome
    Erika Fiorentini, Laura Giunti, Andrea Di Rita, Simone Peraio, Carla Fonte, Chiara Caporalini, Anna Maria Buccoliero, Maria Luigia Censullo, Giulia Gori, Alice Noris, Rosa Pasquariello, Roberta Battini, Rossana Pavone, Flavio Giordano, Sabrina Giglio, Ber
    European Journal of Medical Genetics.2023; 66(7): 104784.     CrossRef
  • Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas
    Liguo Ye, Shi’ao Tong, Yaning Wang, Yu Wang, Wenbin Ma
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 9857.     CrossRef
  • Integrated clinical genomic analysis reveals xenobiotic metabolic genes are downregulated in meningiomas of current smokers
    A. Basit Khan, Rajan Patel, Malcolm F. McDonald, Eric Goethe, Collin English, Ron Gadot, Arya Shetty, Shervin Hosseingholi Nouri, Arif O. Harmanci, Akdes S. Harmanci, Tiemo J. Klisch, Akash J. Patel
    Journal of Neuro-Oncology.2023; 163(2): 397.     CrossRef
  • DNA methylation meningioma biomarkers: attributes and limitations
    Zhaohui Li, Yufei Gao, Jinnan Zhang, Liang Han, Hang Zhao
    Frontiers in Molecular Neuroscience.2023;[Epub]     CrossRef
  • Meningioma: A Biography—Tumor Forever Tied to the Origins and “Soul of Neurosurgery”
    Nolan J. Brown, Zach Pennington, Cathleen C. Kuo, Julian Gendreau, Sachiv Chakravarti, Rohin Singh, Dontré M. Douse, Jamie J. Van Gompel
    World Neurosurgery.2023; 178: 191.     CrossRef
  • Molecular genetic features of meningiomas
    E.S. Makashova, N.V. Lasunin, M.V. Galkin, S.V. Zolotova, K.O. Karandasheva, A.V. Golanov
    Voprosy neirokhirurgii imeni N.N. Burdenko.2023; 87(4): 101.     CrossRef
  • Novel Advances in Treatment of Meningiomas: Prognostic and Therapeutic Implications
    Gerardo Caruso, Rosamaria Ferrarotto, Antonello Curcio, Luisa Metro, Francesco Pasqualetti, Paola Gaviani, Valeria Barresi, Filippo Flavio Angileri, Maria Caffo
    Cancers.2023; 15(18): 4521.     CrossRef
  • Update on meningioma: Clinical-radiological and radio-pathological correlation
    A. Navarro-Ballester, M. Aleixandre-Barrachina, S.F. Marco-Doménech
    Radiología (English Edition).2023; 65(5): 458.     CrossRef
  • Early Preventive Strategies and CNS Meningioma – Is This Feasible? A Comprehensive Review of the Literature
    Daniel Sescu, Aminta Chansiriwongs, Katarzyna Julia Minta, Jyothi Vasudevan, Chandrasekaran Kaliaperumal
    World Neurosurgery.2023; 180: 123.     CrossRef
  • Domestic Animal Models of Central Nervous System Tumors: Focus on Meningiomas
    Michele Tomanelli, Tullio Florio, Gabriela Vargas, Aldo Pagano, Paola Modesto
    Life.2023; 13(12): 2284.     CrossRef
  • The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications
    Stephanie M. Robert, Shaurey Vetsa, Arushii Nadar, Sagar Vasandani, Mark W. Youngblood, Evan Gorelick, Lan Jin, Neelan Marianayagam, E Zeynep Erson-Omay, Murat Günel, Jennifer Moliterno
    Journal of Neuro-Oncology.2022; 156(2): 205.     CrossRef
  • Clinical presentation, diagnostic findings and outcome of dogs undergoing surgical resection for intracranial meningioma: 101 dogs
    Alexander K. Forward, Holger Andreas Volk, Giunio Bruto Cherubini, Tom Harcourt-Brown, Ioannis N. Plessas, Laurent Garosi, Steven De Decker
    BMC Veterinary Research.2022;[Epub]     CrossRef
  • Sphenoid wing meningiomas: peritumoral brain edema as a prognostic factor in surgical outcome
    Abdalrahman Nassar, Volodymyr Smolanka, Andriy Smolanka, Dipak Chaulagain, Oleg Devinyak
    Neurosurgical Review.2022; 45(4): 2951.     CrossRef
  • Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature
    Wenjie Peng, Pei Wu, Minghao Yuan, Bo Yuan, Lian Zhu, Jiesong Zhou, Qian Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Case Report: Upper Thoracic Purely Extradural Spinal Meningioma With Nerve Root Attachment: A Case Report and Literature Review
    Zhao-Lin Wang, Jian-Hui Mou, Dong Sun, Peng Liu
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Molecular diagnosis and treatment of meningiomas: an expert consensus (2022)
    Jiaojiao Deng, Lingyang Hua, Liuguan Bian, Hong Chen, Ligang Chen, Hongwei Cheng, Changwu Dou, Dangmurenjiapu Geng, Tao Hong, Hongming Ji, Yugang Jiang, Qing Lan, Gang Li, Zhixiong Liu, Songtao Qi, Yan Qu, Songsheng Shi, Xiaochuan Sun, Haijun Wang, Yongpi
    Chinese Medical Journal.2022; 135(16): 1894.     CrossRef
  • Оновлена інформація про менінгіоми крила клиноподібної кістки
    Abdalrahman Nassar, Volodymyr Smolanka
    INTERNATIONAL NEUROLOGICAL JOURNAL.2022; 18(1): 43.     CrossRef
  • The Prognostic Value of Methylation Signatures and NF2 Mutations in Atypical Meningiomas
    Rahmina Meta, Henning B. Boldt, Bjarne W. Kristensen, Felix Sahm, Wenche Sjursen, Sverre H. Torp
    Cancers.2021; 13(6): 1262.     CrossRef
  • Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis
    Suha Bachir, Sanjit Shah, Scott Shapiro, Abigail Koehler, Abdelkader Mahammedi, Ravi N. Samy, Mario Zuccarello, Elizabeth Schorry, Soma Sengupta
    International Journal of Molecular Sciences.2021; 22(2): 690.     CrossRef
  • Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions
    Christian Ogasawara, Brandon D. Philbrick, D. Cory Adamson
    Biomedicines.2021; 9(3): 319.     CrossRef
  • The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma
    Minsun Jung, Seong-Ik Kim, Ka Young Lim, Jeongmo Bae, Chul-Kee Park, Seung Hong Choi, Sung-Hye Park, Jae-Kyung Won
    Human Pathology.2021; 115: 96.     CrossRef
  • Papillary Meningioma: Case Presentation with Emphasis on Surgical and Medical Therapy of a Rare Variant of Meningioma
    Gerardo Cazzato, Valeria Internò, Antonietta Cimmino, Raffaella Messina, Marco Tucci, Teresa Lettini, Leonardo Resta, Giuseppe Ingravallo
    Diseases.2021; 9(3): 63.     CrossRef
  • An Overview of Managements in Meningiomas
    Lianhua Zhao, Wei Zhao, Yanwei Hou, Cuixia Wen, Jing Wang, Pei Wu, Zaiyu Guo
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Multi-Omics Analysis in Initiation and Progression of Meningiomas: From Pathogenesis to Diagnosis
    Jiachen Liu, Congcong Xia, Gaiqing Wang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Molecular Mechanism and Approach in Progression of Meningioma
    Zhiwei Shao, Lihong Liu, Yanghao Zheng, Sheng Tu, Yuanbo Pan, Sheng Yan, Qichun Wei, Anwen Shao, Jianmin Zhang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Multiple meningiomas: does quantity matter? a population-based survival analysis with underlined age and sex differences
    Andres Ramos-Fresnedo, Ricardo A. Domingo, Tito Vivas-Buitrago, Larry Lundy, Daniel M. Trifiletti, Mark E. Jentoft, Amit B. Desai, Alfredo Quiñones-Hinojosa
    Journal of Neuro-Oncology.2020; 149(3): 413.     CrossRef
  • Meningioma: A Review of Clinicopathological and Molecular Aspects
    Kristin Huntoon, Angus Martin Shaw Toland, Sonika Dahiya
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Neues zur Einteilung und Therapie von Meningeomen
    Corinna Seliger, Wolfgang Wick
    Neurologie up2date.2020; 3(04): 343.     CrossRef
2019 Practice guidelines for thyroid core needle biopsy: a report of the Clinical Practice Guidelines Development Committee of the Korean Thyroid Association
Chan Kwon Jung, Jung Hwan Baek, Dong Gyu Na, Young Lyun Oh, Ka Hee Yi, Ho-Cheol Kang
J Pathol Transl Med. 2020;54(1):64-86.   Published online January 15, 2020
DOI: https://doi.org/10.4132/jptm.2019.12.04
  • 18,825 View
  • 856 Download
  • 29 Web of Science
  • 32 Crossref
AbstractAbstract PDF
Ultrasound-guided core needle biopsy (CNB) has been increasingly used for the pre-operative diagnosis of thyroid nodules. Since the Korean Society of the Thyroid Radiology published the ‘Consensus Statement and Recommendations for Thyroid CNB’ in 2017 and the Korean Endocrine Pathology Thyroid CNB Study Group published ‘Pathology Reporting of Thyroid Core Needle Biopsy’ in 2015, advances have occurred rapidly not only in the management guidelines for thyroid nodules but also in the diagnostic terminology and classification schemes. The Clinical Practice Guidelines Development Committee of the Korean Thyroid Association (KTA) reviewed publications on thyroid CNB from 1995 to September 2019 and updated the recommendations and statements for the diagnosis and management of thyroid nodules using CNB. Recommendations for the resolution of clinical controversies regarding the use of CNB were based on expert opinion. These practical guidelines include recommendations and statements regarding indications for CNB, patient preparation, CNB technique, biopsy-related complications, biopsy specimen preparation and processing, and pathology interpretation and reporting of thyroid CNB.

Citations

Citations to this article as recorded by  
  • A comparative analysis of core needle biopsy and repeat fine needle aspiration in patients with inconclusive initial cytology of thyroid nodules
    Xuejiao Su, Can Yue, Wanting Yang, Buyun Ma
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • A Narrative Review of the 2023 Korean Thyroid Association Management Guideline for Patients with Thyroid Nodules
    Eun Kyung Lee, Young Joo Park, Chan Kwon Jung, Dong Gyu Na
    Endocrinology and Metabolism.2024; 39(1): 61.     CrossRef
  • Doing more with less: integrating small biopsies in cytology practice
    Anjali Saqi, Michiya Nishino, Mauro Saieg, Amy Ly, Abberly Lott Limbach
    Journal of the American Society of Cytopathology.2024;[Epub]     CrossRef
  • 2023 Update of the Korean Thyroid Association Guidelines for the Management of Thyroid Nodules
    Eun Kyung Lee, Young Joo Park
    Clinical Thyroidology®.2024; 36(4): 153.     CrossRef
  • Risk of thyroid cancer in a lung cancer screening population of the National Lung Screening Trial according to the presence of incidental thyroid nodules detected on low-dose chest CT
    Hyobin Seo, Kwang Nam Jin, Ji Sang Park, Koung Mi Kang, Eun Kyung Lee, Ji Ye Lee, Roh-Eul Yoo, Young Joo Park, Ji-hoon Kim
    Ultrasonography.2023; 42(2): 275.     CrossRef
  • Preoperative Risk Stratification of Follicular-patterned Thyroid Lesions on Core Needle Biopsy by Histologic Subtyping and RAS Variant-specific Immunohistochemistry
    Meejeong Kim, Sora Jeon, Chan Kwon Jung
    Endocrine Pathology.2023; 34(2): 247.     CrossRef
  • Differential regional importance mapping for thyroid nodule malignancy prediction with potential to improve needle aspiration biopsy sampling reliability
    Liping Wang, Yuan Wang, Wenliang Lu, Dong Xu, Jincao Yao, Lijing Wang, Lei Xu
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Preoperative evaluation of thyroid nodules – Diagnosis and management strategies
    Tapoi Dana Antonia, Lambrescu Ioana Maria, Gheorghisan-Galateanu Ancuta-Augustina
    Pathology - Research and Practice.2023; 246: 154516.     CrossRef
  • 2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules
    Young Joo Park, Eun Kyung Lee, Young Shin Song, Soo Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung
    International Journal of Thyroidology.2023; 16(1): 1.     CrossRef
  • Fast Track Management of Primary Thyroid Lymphoma in the Very Elderly Patient
    Pierre Yves Marcy, Frederic Bauduer, Juliette Thariat, Olivier Gisserot, Edouard Ghanassia, Bruno Chetaille, Laurys Boudin, Jean Baptiste Morvan
    Current Oncology.2023; 30(6): 5816.     CrossRef
  • Reevaluating diagnostic categories and associated malignancy risks in thyroid core needle biopsy
    Chan Kwon Jung
    Journal of Pathology and Translational Medicine.2023; 57(4): 208.     CrossRef
  • Diagnostic performance of shear wave elastography in thyroid nodules with indeterminate cytology: A systematic review and meta-analysis
    Yuxuan Qiu, Zhichao Xing, Qianru Yang, Yan Luo, Buyun Ma
    Heliyon.2023; 9(10): e20654.     CrossRef
  • Comparison of the diagnostic value of fine needle aspiration and ultrasound in thyroid pathology
    P. S. Glushkov, R. Kh. Azimov, N. L. Aleshenko, E. A. Maruchak, Y. P. Sych, G. N. Minkova, K. A. Shemyatovsky, V. A. Gorsky
    Endocrine Surgery.2023; 17(3): 43.     CrossRef
  • Comparison of Core Needle Biopsy and Repeat Fine-Needle Aspiration in Avoiding Diagnostic Surgery for Thyroid Nodules Initially Diagnosed as Atypia/Follicular Lesion of Undetermined Significance
    Leehi Joo, Dong Gyu Na, Ji-hoon Kim, Hyobin Seo
    Korean Journal of Radiology.2022; 23(2): 280.     CrossRef
  • Diagnostic efficacy, performance and safety of side-cut core needle biopsy for thyroid nodules: comparison of automated and semi-automated biopsy needles
    Ji Yeon Park, Seong Yoon Yi, Soo Heui Baek, Yu Hyun Lee, Heon-Ju Kwon, Hee Jin Park
    Endocrine.2022; 76(2): 341.     CrossRef
  • Thyroid Cancer Diagnostics Related to Occupational and Environmental Risk Factors: An Integrated Risk Assessment Approach
    Gabriela Maria Berinde, Andreea Iulia Socaciu, Mihai Adrian Socaciu, Andreea Cozma, Armand Gabriel Rajnoveanu, Gabriel Emil Petre, Doina Piciu
    Diagnostics.2022; 12(2): 318.     CrossRef
  • Approach to Bethesda system category III thyroid nodules according to US-risk stratification
    Jieun Kim, Jung Hee Shin, Young Lyun Oh, Soo Yeon Hahn, Ko Woon Park
    Endocrine Journal.2022; 69(1): 67.     CrossRef
  • Clinicopathological and Molecular Features of Secondary Cancer (Metastasis) to the Thyroid and Advances in Management
    Marie Nguyen, George He, Alfred King-Yin Lam
    International Journal of Molecular Sciences.2022; 23(6): 3242.     CrossRef
  • Diagnostic Performance of Thyroid Core Needle Biopsy Using the Revised Reporting System: Comparison with Fine Needle Aspiration Cytology
    Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, So Lyung Jung, Chan Kwon Jung
    Endocrinology and Metabolism.2022; 37(1): 159.     CrossRef
  • Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses
    Antonio Matrone, Luigi De Napoli, Liborio Torregrossa, Aleksandr Aghababyan, Piermarco Papini, Carlo Enrico Ambrosini, Rosa Cervelli, Clara Ugolini, Fulvio Basolo, Eleonora Molinaro, Rossella Elisei, Gabriele Materazzi
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Primary thyroid leiomyosarcoma with transvenous extension to the right atrium: a case report
    Juraj Dubrava, Peter Martanovic, Marina Pavlovicova, Pavel Babal, Akhil Narang, Maria Mattioli, Nidhish Tiwari, Zhiyu Liu, Mariame Chakir
    European Heart Journal - Case Reports.2022;[Epub]     CrossRef
  • Radiofrequency ablation for management of thyroid nodules in quarantine zone of COVID-19 pandemic setting in Indonesia
    Kristanto Yuli Yarso, Sumadi Lukman Anwar
    Annals of Medicine and Surgery.2022; 81: 104132.     CrossRef
  • A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model
    Faridul Haq, Andrey Bychkov, Chan Kwon Jung
    Endocrine Pathology.2022; 33(4): 472.     CrossRef
  • Diagnostic performance of core needle biopsy as a first‐line diagnostic tool for thyroid nodules according to ultrasound patterns: Comparison with fine needle aspiration using propensity score matching analysis
    Hye Shin Ahn, Inyoung Youn, Dong Gyu Na, Soo Jin Kim, Mi Yeon Lee
    Clinical Endocrinology.2021; 94(3): 494.     CrossRef
  • Hydrodissection: A Novel Approach for Safe Core Needle Biopsy of Small High-Risk Subcapsular Thyroid Nodules
    Hojat Ebrahiminik, Hossein Chegeni, Javad Jalili, Rambod Salouti, Hadi Rokni, Afshin Mohammadi, Ali Mosaddegh Khah, Seyed Mohammad Tavangar, Zahra Ebrahiminik
    CardioVascular and Interventional Radiology.2021; 44(10): 1651.     CrossRef
  • Application of biomarkers in the diagnosis of uncertain samples of core needle biopsy of thyroid nodules
    Yan Xiong, Xin Li, Li Liang, Dong Li, Limin Yan, Xueying Li, Jiting Di, Ting Li
    Virchows Archiv.2021; 479(5): 961.     CrossRef
  • VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients
    Faiza A. Rashid, Sobia Tabassum, Mosin S. Khan, Hifzur R. Ansari, Muhammad Asif, Ahmareen K. Sheikh, Syed Sameer Aga
    Journal of Clinical Laboratory Analysis.2021;[Epub]     CrossRef
  • The Diagnostic Value of the American College of Radiology Thyroid Imaging Reporting and Data System Classification and Shear-Wave Elastography for the Differentiation of Thyroid Nodules
    Gül Bora Makal, Aydın Aslan
    Ultrasound in Medicine & Biology.2021; 47(5): 1227.     CrossRef
  • Comparison of the diagnostic performance of the modified Korean Thyroid Imaging Reporting and Data System for thyroid malignancy with three international guidelines
    Eun Ju Ha, Jung Hee Shin, Dong Gyu Na, So Lyung Jung, Young Hen Lee, Wooyul Paik, Min Ji Hong, Yeo Koon Kim, Chang Yoon Lee
    Ultrasonography.2021; 40(4): 594.     CrossRef
  • VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer
    Sonam Choden, Somboon Keelawat, Chan Kwon Jung, Andrey Bychkov
    Cancers.2020; 12(3): 596.     CrossRef
  • The 2019 core-needle biopsy practice guidelines
    So Yeong Jeong, Jung Hwan Baek
    Ultrasonography.2020; 39(3): 311.     CrossRef
  • Re: The 2019 core-needle biopsy practice guidelines
    Ji-hoon Kim
    Ultrasonography.2020; 39(3): 313.     CrossRef
Original Articles
Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer
Ye Sul Jeong, Jun Kang, Jieun Lee, Tae-Kyung Yoo, Sung Hun Kim, Ahwon Lee
J Pathol Transl Med. 2020;54(1):87-94.   Published online November 13, 2019
DOI: https://doi.org/10.4132/jptm.2019.10.14
  • 6,105 View
  • 194 Download
  • 13 Web of Science
  • 14 Crossref
AbstractAbstract PDF
Background
Accurate molecular classification of breast core needle biopsy (CNB) tissue is important for determining neoadjuvant systemic therapies for invasive breast cancer. The researchers aimed to evaluate the concordance rate (CR) of molecular subtypes between CNBs and surgical specimens.
Methods
This study was conducted with invasive breast cancer patients who underwent surgery after CNB at Seoul St. Mary’s Hospital between December 2014 and December 2017. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 were analyzed using immunohistochemistry. ER and PR were evaluated by Allred score (0–8). HER2 was graded from 0 to +3, and all 2+ cases were reflex tested with silver in situ hybridization. The labeling index of Ki67 was counted by either manual scoring or digital image analysis. Molecular subtypes were classified using the above surrogate markers.
Results
In total, 629 patients were evaluated. The CRs of ER, PR, HER2, and Ki67 were 96.5% (kappa, 0.883; p<.001), 93.0% (kappa, 0.824; p<.001), 99.7% (kappa, 0.988; p<.001), and 78.7% (kappa, 0.577; p<.001), respectively. Digital image analysis of Ki67 in CNB showed better concordance with Ki67 in surgical specimens (CR, 82.3%; kappa, 0.639 for digital image analysis vs. CR, 76.2%; kappa, 0.534 for manual counting). The CRs of luminal A, luminal B, HER2, and triple negative types were 89.0%, 70.0%, 82.9%, and 77.2%, respectively.
Conclusions
CNB was reasonably accurate for determining ER, PR, HER2, Ki67, and molecular subtypes. Using digital image analysis for Ki67 in CNB produced more accurate molecular classifications.

Citations

Citations to this article as recorded by  
  • Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature
    Chiara Rossi, Sara Fraticelli, Marianna Fanizza, Alberta Ferrari, Elisa Ferraris, Alessia Messina, Angelica Della Valle, Chiara Annunziata Pasqualina Anghelone, Angioletta Lasagna, Gianpiero Rizzo, Lorenzo Perrone, Maria Grazia Sommaruga, Giulia Meloni, S
    Breast Cancer Research and Treatment.2023; 198(3): 573.     CrossRef
  • Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor
    Su Hwa Kim, Young Suk Lee, Sung Hak Lee, Yeoun Eun Sung, Ahwon Lee, Jun Kang, Jae-Sung Park, Sin Soo Jeun, Youn Soo Lee
    Journal of Pathology and Translational Medicine.2023; 57(4): 217.     CrossRef
  • The Role of Diffusion-Weighted Imaging Based on Maximum-Intensity Projection in Young Patients with Marked Background Parenchymal Enhancement on Contrast-Enhanced Breast MRI
    Ga-Eun Park, Bong-Joo Kang, Sung-hun Kim, Na-Young Jung
    Life.2023; 13(8): 1744.     CrossRef
  • Concordance between core needle biopsy and surgical excision specimens for Ki‐67 in breast cancer – a systematic review of the literature
    Jahnavi Kalvala, Ruth M Parks, Andrew R Green, Kwok‐Leung Cheung
    Histopathology.2022; 80(3): 468.     CrossRef
  • İnvaziv Meme Kanserinde Preoperatif Kor İğne Biyopsi ile Postoperatif Cerrahi Spesmenler Arasında ER, PR, HER2 ve Ki67 Açısından Karşılaştırma
    Pınar CELEPLİ, Pelin Seher ÖZTEKİN, Salih CELEPLİ, İrem BİGAT, Sema HÜCÜMENOĞLU
    Akdeniz Medical Journal.2022; : 179.     CrossRef
  • Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience
    Jessica A. Slostad, Nicole K. Yun, Aimee E. Schad, Surbhi Warrior, Louis F. Fogg, Ruta Rao
    Cancer Medicine.2022; 11(24): 4954.     CrossRef
  • N-Cadherin Distinguishes Intrahepatic Cholangiocarcinoma from Liver Metastases of Ductal Adenocarcinoma of the Pancreas
    Tiemo S. Gerber, Benjamin Goeppert, Anne Hausen, Hagen R. Witzel, Fabian Bartsch, Mario Schindeldecker, Lisa-Katharina Gröger, Dirk A. Ridder, Oscar Cahyadi, Irene Esposito, Matthias M. Gaida, Peter Schirmacher, Peter R. Galle, Hauke Lang, Wilfried Roth,
    Cancers.2022; 14(13): 3091.     CrossRef
  • Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2− Early Breast Cancer Patients
    Shuai Li, Xiaosong Chen, Kunwei Shen
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • MRI Features for Prediction Malignant Intra-Mammary Lymph Nodes: Correlations with Mammography and Ultrasound
    Meejung Kim, Bong Joo Kang, Ga Eun Park
    Investigative Magnetic Resonance Imaging.2022; 26(2): 135.     CrossRef
  • A single centre experience in Turkey for comparison between core needle biopsy and surgical specimen evaluation results for HER2, SISH, estrogen receptors and progesterone receptors in breast cancer patients
    Hatice Karaman, Fatma Senel, Arzu Tasdemir, Ipek Özer, Merve Dogan
    Journal of Cancer Research and Therapeutics.2022; 18(6): 1789.     CrossRef
  • Meme kanseri trucut ve rezeksiyon materyallerinde yeni moleküler sınıflama, tanı ve hormon reseptörlerinin durumu tutarlı mı?
    Yeliz ARMAN KARAKAYA, Sevda YILMAZ, Hande KARABAŞ
    Pamukkale Medical Journal.2021;[Epub]     CrossRef
  • What shear wave elastography parameter best differentiates breast cancer and predicts its histologic aggressiveness?
    Hyunjin Kim, Jeongmin Lee, Bong Joo Kang, Sung Hun Kim
    Ultrasonography.2021; 40(2): 265.     CrossRef
  • Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
    Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart
    Cancer Treatment Reviews.2021; 99: 102229.     CrossRef
  • Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens
    Kristina A. Tendl-Schulz, Fabian Rössler, Philipp Wimmer, Ulrike M. Heber, Martina Mittlböck, Nicolas Kozakowski, Katja Pinker, Rupert Bartsch, Peter Dubsky, Florian Fitzal, Martin Filipits, Fanny Carolina Eckel, Eva-Maria Langthaler, Günther Steger, Mich
    Virchows Archiv.2020; 477(4): 545.     CrossRef
Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
Yunjeong Jang, Hera Jung, Han-Na Kim, Youjeong Seo, Emad Alsharif, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Yeon Hee Park, Eun Yoon Cho, Soo Youn Cho
J Pathol Transl Med. 2020;54(1):95-102.   Published online November 13, 2019
DOI: https://doi.org/10.4132/jptm.2019.10.24
  • 6,857 View
  • 263 Download
  • 17 Web of Science
  • 15 Crossref
AbstractAbstract PDF
Background
Pure mucinous carcinoma (PMC) is a rare type of breast cancer, estimated to represent 2% of invasive breast cancer. PMC is typically positive for estrogen receptors (ER) and progesterone receptors (PR) and negative for human epidermal growth factor receptor 2 (HER2). The clinicopathologic characteristics of HER2-positive PMC have not been investigated.
Methods
Pathology archives were searched for PMC diagnosed from January 1999 to April 2018. Clinicopathologic data and microscopic findings were reviewed and compared between HER2-positive PMC and HER2-negative PMC. We also analyzed the differences in disease-free survival (DFS) and overall survival according to clinicopathologic parameters including HER2 status in overall PMC cases.
Results
There were 21 HER2-positive cases (4.8%) in 438 PMCs. The average tumor size of HER2-positive PMC was 32.21 mm (± 26.55). Lymph node metastasis was present in seven cases. Compared to HER2-negative PMC, HER2-positive PMC presented with a more advanced T category (p < .001), more frequent lymph node metastasis (p = .009), and a higher nuclear and histologic grade (p < .001). Microscopically, signet ring cells were frequently observed in HER2-positive PMC (p < .001), whereas a micropapillary pattern was more frequent in HER2-negative PMC (p = .012). HER2-positive PMC was more frequently negative for ER (33.3% vs. 1.2%) and PR (28.6% vs. 7.2%) than HER2-negative PMC and showed a high Ki-67 labeling index. During follow-up, distant metastasis and recurrence developed in three HER2-positive PMC patients. Multivariate analysis revealed that only HER2-positivity and lymph node status were significantly associated with DFS.
Conclusions
Our results suggest that HER2-positive PMC is a more aggressive subgroup of PMC. HER2 positivity should be considered for adequate management of PMC.

Citations

Citations to this article as recorded by  
  • Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in Low-grade Endometrial Endometrioid Carcinoma
    Yurimi Lee, Sangjoon Choi, Hyun-Soo Kim
    International Journal of Gynecological Pathology.2024; 43(3): 221.     CrossRef
  • Pure Mucinous Carcinoma of the Breast: Radiologic-Pathologic Correlation
    Cherie M Kuzmiak, Benjamin C Calhoun
    Journal of Breast Imaging.2023;[Epub]     CrossRef
  • Role of circ-FOXO3 and miR-23a in radiosensitivity of breast cancer
    Elahe Abdollahi, Hossein Mozdarani, Behrooz Z. Alizadeh
    Breast Cancer.2023; 30(5): 714.     CrossRef
  • On Ultrasonographic Features of Mucinous Carcinoma with Micropapillary Pattern
    Wei-Sen Yang, Yang Li, Ya Gao
    Breast Cancer: Targets and Therapy.2023; Volume 15: 473.     CrossRef
  • Spectrum of Mucin-containing Lesions of the Breast: Multimodality Imaging Review with Pathologic Correlation
    Janice N. Thai, Melinda F. Lerwill, Shinn-Huey S. Chou
    RadioGraphics.2023;[Epub]     CrossRef
  • Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics
    Hyun Hee Koh, Eunhyang Park, Hyun-Soo Kim
    Diagnostics.2022; 12(2): 326.     CrossRef
  • Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics
    Yurimi Lee, Kiyong Na, Ha Young Woo, Hyun-Soo Kim
    Diagnostics.2022; 12(5): 1102.     CrossRef
  • Metastasis of the Mucionous adenocarcinoma of breast to the mandibular gingiva: Rare case report
    Ivana Mijatov, Aleksandra Fejsa Levakov, Aleksandar Spasić, Jelena Nikolić, Saša Mijatov
    Medicine.2022; 101(38): e30732.     CrossRef
  • Endometrioid Carcinomas of the Ovaries and Endometrium Involving Endocervical Polyps: Comprehensive Clinicopathological Analyses
    Jihee Sohn, Yurimi Lee, Hyun-Soo Kim
    Diagnostics.2022; 12(10): 2339.     CrossRef
  • Serous Carcinoma of the Endometrium with Mesonephric-Like Differentiation Initially Misdiagnosed as Uterine Mesonephric-Like Adenocarcinoma: A Case Report with Emphasis on the Immunostaining and the Identification of Splice Site TP53 Mutation
    Sangjoon Choi, Yoon Yang Jung, Hyun-Soo Kim
    Diagnostics.2021; 11(4): 717.     CrossRef
  • HER2 positive mucinous carcinoma of breast with micropapillary features: Report of a case and review of literature
    Dinesh Chandra Doval, Rupal Tripathi, Sunil Pasricha, Pankaj Goyal, Chaturbhuj Agrawal, Anurag Mehta
    Human Pathology: Case Reports.2021; 25: 200531.     CrossRef
  • Carcinoma mucosecretor de mama HER2-positivo, un caso clínico
    A.M. González Aranda, E. Martínez Gómez, A. Santana Costa, F. Arnanz Velasco, M.H. González de Diego, A. Zapico Goñi
    Clínica e Investigación en Ginecología y Obstetricia.2021; 48(4): 100685.     CrossRef
  • Clinicopathologic features of unexpectedly HER2 positive breast carcinomas: An institutional experience
    Carissa LaBoy, Kalliopi P. Siziopikou, Lauren Rosen, Luis Z. Blanco, Jennifer L. Pincus
    Pathology - Research and Practice.2021; 222: 153441.     CrossRef
  • Mesonephric-like Differentiation of Endometrial Endometrioid Carcinoma: Clinicopathological and Molecular Characteristics Distinct from Those of Uterine Mesonephric-like Adenocarcinoma
    Sujin Park, Go Eun Bae, Jiyoung Kim, Hyun-Soo Kim
    Diagnostics.2021; 11(8): 1450.     CrossRef
  • Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comprehensive Immunohistochemical Analyses Using Markers for Mesonephric, Endometrioid and Serous Tumors
    Hyunjin Kim, Kiyong Na, Go Eun Bae, Hyun-Soo Kim
    Diagnostics.2021; 11(11): 2042.     CrossRef
Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma
Jin Hwan Lee, Han Kyeom Kim, Bong Kyung Shin
J Pathol Transl Med. 2020;54(1):103-111.   Published online November 13, 2019
DOI: https://doi.org/10.4132/jptm.2019.10.12
  • 5,300 View
  • 133 Download
  • 4 Web of Science
  • 3 Crossref
AbstractAbstract PDF
Background
Adenocarcinoma (ADC) of the lung exhibits different clinicopathological characteristics in men and women. Recent studies have suggested that these differences originate from the expression of female sex hormone receptors in tumor cells. The aim of the present study was to evaluate the immunohistochemical expression of female sex hormone receptors in lung ADC and determine the expression patterns in patients with different clinicopathological characteristics.
Methods
A total of 84 patients with lung ADC who underwent surgical resection and/or core biopsy were recruited for the present study. Immunohistochemical staining was performed for estrogen receptor α (ERα), estrogen receptor β (ERβ), progesterone receptor (PR), epidermal growth factor receptor (EGFR), EGFR E746- A750 del, and EGFR L858R using tissue microarray.
Results
A total of 39 (46.4%) ERα-positive, 71 (84.5%) ERβ-positive, and 46 (54.8%) PR-positive lung ADCs were identified. In addition, there were 81 (96.4%) EGFR-positive, 14 (16.7%) EGFR E746-A750 del–positive, and 34 (40.5%) EGFR L858R–positive cases. The expression of female sex hormone receptors was not significantly different in clinicopathologically different subsets of lung ADC.
Conclusions
Expression of female sex hormone receptors is not associated with the prognosis and clinicopathological characteristics of patients with lung ADC.

Citations

Citations to this article as recorded by  
  • Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review
    Carmine Valenza, Francesca Maria Porta, Alessandra Rappa, Elena Guerini-Rocco, Giuseppe Viale, Massimo Barberis, Filippo de Marinis, Giuseppe Curigliano, Chiara Catania
    Current Oncology.2021; 28(5): 3384.     CrossRef
  • Development of a 15-Gene Signature Model as a Prognostic Tool in Sex Hormone-Dependent Cancers
    Zhi Xia, Jian Xiao, Aibin Liu, Qiong Chen, Arumugam R. Jayakumar
    BioMed Research International.2021; 2021: 1.     CrossRef
  • Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
    Nuria Mederos, Alex Friedlaender, Solange Peters, Alfredo Addeo
    ESMO Open.2020; 5(Suppl 4): e000796.     CrossRef
Comparison of papanicolaou smear and human papillomavirus (HPV) test as cervical screening tools: can we rely on HPV test alone as a screening method? An 11-year retrospective experience at a single institution
Myunghee Kang, Seung Yeon Ha, Hyun Yee Cho, Dong Hae Chung, Na Rae Kim, Jungsuk An, Sangho Lee, Jae Yeon Seok, Juhyeon Jeong
J Pathol Transl Med. 2020;54(1):112-118.   Published online January 15, 2020
DOI: https://doi.org/10.4132/jptm.2019.11.29
  • 7,653 View
  • 214 Download
  • 11 Web of Science
  • 10 Crossref
AbstractAbstract PDF
Background
The decrease in incidence of cervical dysplasia and carcinoma has not been as dramatic as expected with the development of improved research tools and test methods. The human papillomavirus (HPV) test alone has been suggested for screening in some countries. The National Cancer Screening Project in Korea has applied Papanicolaou smears (Pap smears) as the screening method for cervical dysplasia and carcinoma. We evaluated the value of Pap smear and HPV testing as diagnostic screening tools in a single institution.
Methods
Patients co-tested with HPV test and Pap smear simultaneously or within one month of each other were included in this study. Patients with only punch biopsy results were excluded because of sampling errors. A total of 999 cases were included, and the collected reports encompassed results of smear cytology, HPV subtypes, and histologic examinations.
Results
Sensitivity and specificity of detecting high-grade squamous intraepithelial lesion (HSIL) and squamous cell carcinoma (SCC) were higher for Pap smears than for HPV tests (sensitivity, 97.14%; specificity, 85.58% for Pap smears; sensitivity, 88.32%; specificity, 54.92% for HPV tests). HPV tests and Pap smears did not differ greatly in detection of low-grade squamous intraepithelial lesion (85.35% for HPV test, 80.31% for Pap smears). When atypical glandular cells were noted on Pap smears, the likelihood for histologic diagnosis of adenocarcinoma following Pap smear was higher than that of high-risk HPV test results (18.8 and 1.53, respectively).
Conclusions
Pap smears were more useful than HPV tests in the diagnosis of HSIL, SCC, and glandular lesions.

Citations

Citations to this article as recorded by  
  • Challenges in the diagmosis of cervical pathologies
    D. Y. Chernov, O. A. Tikhonovskaya, S. V. Logvinov, I. A. Petrov, Y. S. Yuriev, A. A. Zhdankina, A. V. Gerasimov, I. V. Zingalyuk, G. A. Mikheenko
    Bulletin of Siberian Medicine.2024; 22(4): 201.     CrossRef
  • Selection of endogenous control and identification of significant microRNA deregulations in cervical cancer
    T. Stverakova, I. Baranova, P. Mikyskova, B. Gajdosova, H. Vosmikova, J. Laco, V. Palicka, H. Parova
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Attitudes towards prevention of cervical cancer and early diagnosis among female academicians
    Nurhan Doğan, Gamze Fışkın
    Journal of Obstetrics and Gynaecology Research.2022; 48(6): 1433.     CrossRef
  • Role of Self-Sampling for Cervical Cancer Screening: Diagnostic Test Properties of Three Tests for the Diagnosis of HPV in Rural Communities of Cuenca, Ecuador
    Bernardo Vega Crespo, Vivian Alejandra Neira, José Ortíz Segarra, Ruth Maldonado Rengel, Diana López, María Paz Orellana, Andrea Gómez, María José Vicuña, Jorge Mejía, Ina Benoy, Tesifón Parrón Carreño, Veronique Verhoeven
    International Journal of Environmental Research and Public Health.2022; 19(8): 4619.     CrossRef
  • Utility of Scoring System for Screening and Early Warning of Cervical Cancer Based on Big Data Analysis
    Dan Hou, Binjie Yang, Yangdan Li, Ming Sun
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Evaluation of Urine and Vaginal Self-Sampling versus Clinician-Based Sampling for Cervical Cancer Screening: A Field Comparison of the Acceptability of Three Sampling Tests in a Rural Community of Cuenca, Ecuador
    Bernardo Vega Crespo, Vivian Alejandra Neira, José Ortíz S, Ruth Maldonado-Rengel, Diana López, Andrea Gómez, María José Vicuña, Jorge Mejía, Ina Benoy, Tesifón Parrón Carreño, Veronique Verhoeven
    Healthcare.2022; 10(9): 1614.     CrossRef
  • Diagnostic distribution and pitfalls of glandular abnormalities in cervical cytology: a 25-year single-center study
    Jung-A Sung, Ilias P. Nikas, Haeryoung Kim, Han Suk Ryu, Cheol Lee
    Journal of Pathology and Translational Medicine.2022; 56(6): 354.     CrossRef
  • Comparison of Learning Transfer Using Simulation Problem-Based Learning and Demonstration: An Application of Papanicolaou Smear Nursing Education
    Jeongim Lee, Hae Kyoung Son
    International Journal of Environmental Research and Public Health.2021; 18(4): 1765.     CrossRef
  • Investigating host-virus interaction mechanism and phylogenetic analysis of viral proteins involved in the pathogenesis
    Ahmad Abu Turab Naqvi, Farah Anjum, Alaa Shafie, Sufian Badar, Abdelbaset Mohamed Elasbali, Dharmendra Kumar Yadav, Md. Imtaiyaz Hassan, Timir Tripathi
    PLOS ONE.2021; 16(12): e0261497.     CrossRef
  • Utility of Human Papillomavirus Testing for Cervical Cancer Screening in Korea
    Mee-seon Kim, Eun Hee Lee, Moon-il Park, Jae Seok Lee, Kisu Kim, Mee Sook Roh, Hyoun Wook Lee
    International Journal of Environmental Research and Public Health.2020; 17(5): 1726.     CrossRef
Case Study
Morule-like features in pulmonary adenocarcinoma associated with epidermal growth factor receptor mutations: two case reports with targeted next-generation sequencing analysis
Yoo Jin Lee, Harim Oh, Eojin Kim, Bokyung Ahn, Jeong Hyeon Lee, Youngseok Lee, Yang Seok Chae, Chul Hwan Kim
J Pathol Transl Med. 2020;54(1):119-122.   Published online November 1, 2019
DOI: https://doi.org/10.4132/jptm.2019.09.30
  • 4,330 View
  • 120 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDF
Morules, or morule-like features, can be identified in benign and malignant lesions in various organs. Morular features are unusual in pulmonary adenocarcinoma cases with only 26 cases reported to date. Here, we describe two cases of pulmonary adenocarcinoma with morule-like features in Korean women. One patient had a non-mucinous-type adenocarcinoma in situ and the other had an acinarpredominant adenocarcinoma with a micropapillary component. Both patients showed multiple intra-alveolar, nodular, whorled proliferative foci composed of atypical spindle cells with eosinophilic cytoplasm. Targeted next-generation sequencing was performed on DNA extracted from formalin-fixed paraffin-embedded samples of the tumors. Results showed unusual epidermal growth factor receptor (EGFR) mutations, which are associated with drug resistance to EGFR tyrosine kinase inhibitors, revealing the importance of identifying morule-like features in pulmonary adenocarcinoma and the need for additional study, since there are few reported cases.

Citations

Citations to this article as recorded by  
  • Pulmonary adenocarcinoma in situ with morule - like components: A surgical case report
    Mitsuteru Yosida, Mitsuru Tomita, Naoya Kawakita, Teruki Shimizu, Ryou Yamada, Hiromitsu Takizawa, Hisanori Uehara
    Respiratory Medicine Case Reports.2024; 48: 102008.     CrossRef
  • Clinicopathological, Radiological, and Molecular Features of Primary Lung Adenocarcinoma with Morule-Like Components
    Li-Li Wang, Li Ding, Peng Zhao, Jing-Jing Guan, Xiao-Bin Ji, Xiao-Li Zhou, Shi-Hong Shao, Yu-Wei Zou, Wei-Wei Fu, Dong-Liang Lin, Dong Pan
    Disease Markers.2021; 2021: 1.     CrossRef
Editorial
Papillary thyroid carcinoma variants with tall columnar cells
Chan Kwon Jung
J Pathol Transl Med. 2020;54(1):123-123.   Published online January 15, 2020
DOI: https://doi.org/10.4132/jptm.2019.12.18
  • 4,581 View
  • 157 Download
  • 1 Web of Science
  • 1 Crossref
PDF

Citations

Citations to this article as recorded by  
  • Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification
    Yanhua Bai, Kennichi Kakudo, Chan Kwon Jung
    Endocrinology and Metabolism.2020; 35(4): 696.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine